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In recent years, the field of immunometabolism – the study of how specific changes in cellular 
metabolism regulate the function of diverse immune cell types—has grown exponentially. Several 
in vitro studies have examined the metabolic regulation of natural killer (NK) cells, which are first 
responders for viral infection and malignant transformation; however, much less is known 
regarding the role of metabolism in directing NK cell responses in vivo, such as during viral 
infection. In order to examine how NK cell antiviral function is regulated in vivo, we used a well-
characterized infection with murine cytomegalovirus (MCMV) to assess NK cell cytokine 
production, proliferation, and killing. Two treatments were used to manipulate major metabolic 
pathways: a drug model to examine the role of glycolytic metabolism, and a genetic model to 
examine the role of oxidative metabolism. We found that treatment with the glucose metabolism 
inhibitor 2-deoxy-ᴅ-glucose (2DG) impaired both mouse and human NK cell cytotoxicity 
following priming in vitro. Similarly, MCMV-infected mice treated with 2DG had impaired 
clearance of NK-specific targets in vivo, which was associated with higher viral burdens and 




by pre-treatment with IL-15, which alters NK cell metabolism and metabolic requirements for 
activation. To interrogate the role of oxidative metabolism on NK cell function, we examined 
responses to MCMV in mice with an NK-specific deletion of Cox10, a nuclear gene encoding a 
protein required for functional assembly of mitochondrial electron transport chain Complex IV. 
Cox10-deficient NK cells developed normally, retaining normal function, energy production, and 
oxygen consumption at baseline. However, they had a defect in proliferation when activated 
through the Ly49H receptor in vitro and in vivo. Ly49H recognizes an MCMV-encoded protein 
and mediates preferential expansion of the Ly49H+ NK cell population. The expansion defect in 
Cox10-deficient NK cells was associated with decreased mitochondrial production of reactive 
oxygen species and increased susceptibility to MCMV infection. Thus, we found that uninhibited 
glucose metabolism is required by NK cells for maximal cytotoxic function, and that the oxidative 
pathway gene Cox10 is required by NK cells to proliferate optimally in response to MCMV 
infection. Our findings emphasize that metabolic pathways have specific interactions with 
different immune functions, and further develop methods to investigate metabolic regulation of 




















Part of this chapter is adapted from a manuscript published in Critical Reviews in Immunology: 
Mah AY, Cooper MA. Metabolic Regulation of Natural Killer Cell IFN-g Production. 
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In the last decade, there has been a resurgence of interest amongst immunologists in the 
key role that metabolism plays in regulating immune cell function. In 1958, Otto Warburg 
described but dismissed his observation that proliferating leukocytes use aerobic glycolysis rather 
than the more energy-efficient process of oxidative phosphorylation, thinking his findings were 
experimental artifact. Since then, immunologists have discovered that this “metabolic 
reprogramming” of activated leukocytes toward aerobic glycolysis is critical for immune cell 
function, and have delved into the complex but critical interplay between the immune system and 
metabolic pathways. The study of “immunometabolism” aims to untangle how activation and other 
canonical immunological signals alter cell metabolism, and how metabolic intermediates and 
pathways are able to regulate immune cell effector function in turn.  
We are primarily interested in natural killer (NK) cells, which are cytotoxic cells of the 
innate immune response. The immune regulation of these cells is especially interesting because 
they have characteristics of both the innate and adaptive immune systems. They are functionally 
and developmentally similar to CD8+ T cells, but can act in a shorter time span, meaning that their 
metabolic demands are intrinsically different from T cells. While our understanding of T cells is 
one of the most advanced in the immunometabolism field, few laboratories are actively engaged 
in studying NK cell metabolic regulation. Given their key function in early antiviral and antitumor 
immunity, as well as growing investigation into their therapeutic use, a greater understanding of 
NK cell regulation through their metabolism is needed to be able to manipulate NK cell function. 
Also, given the difficulties in manipulating metabolism in vivo, more methods need to be 
developed in order to interrogate NK cell function in physiological contexts such as during viral 
infection. Thus, we set out to investigate the role of two core metabolic pathways—glycolysis and 




In this dissertation, I will introduce NK cells and their major functions, how other immune 
cells are regulated by metabolism, and what we know so far of how NK cells are metabolically 
regulated. Chapter 2 presents our findings using the drug 2-deoxy-D-glucose to investigate the role 
of glycolysis on NK cell antiviral function in vitro and in vivo, with an emphasis on its role in 
priming cells for cytotoxic function. Chapter 3 presents our ongoing work using a genetic model 
of Cox10 deletion to examine how NK cell response to viral infection, and formation of NK cell 
“memory” is reliant on mitochondrial oxidative metabolism. Finally, I will conclude by discussing 
the implications of our findings for the field of immunometabolism and suggesting future 
directions for related research. 
1.1 Natural Killer Cells and Their Functions 
Natural killer (NK) cells are lymphocytes that comprise approximately 10-15% of human 
peripheral blood mononuclear cells and 2-3% of splenocytes in mice. They are early responders to 
viral infection and malignant transformation, and are critical for the response to these threats before 
T cells become active. They share their role as cytotoxic and interferon gamma (IFN-γ)-producing 
cells with CD8+ T cells. However, unlike T cells which mount an antigen-specific response a week 
after priming, NK cells are antigen-independent, recogne infected and transformed cells through 
germline-encoded NK receptors (NKRs), and kill them within minutes to hours (1-4). NK cells 
can be activated by three complementary and often overlapping routes: 1) engagement of NKRs 
that recognize stress- and virally-induced ligands on target cells in the absence of a strong 
inhibitory receptor signal, 2) recognition of antibody-coated target cells through the activating Fc 
receptor CD16 (antibody-dependent cellular cytotoxicity), and/or 3) activation by innate and 




can lead to three major responses: production of cytokines, killing of infected cells, and 
proliferation. In this section, we emphasize NK cell regulation in response to infection with murine 
cytomegalovirus (MCMV), which we use to interrogate NK cell function in vivo (Fig. 1.1). 
Regulation of NK cell cytokine production 
NK cells produce several cytokines and chemokines that coordinate innate and adaptive 
immune responses, and are the major source of the immunostimulatory and immunomodulatory 
cytokine IFN-γ in the first hours of infection (2). Experimentally, NK cell IFN-γ production can 
be induced by brief incubation (4-24h) with purified cytokines or cytokine-producing antigen 
presenting cells, co-culture with tumor cells expressing activating ligands, or culture with plate- 
or bead-bound antibodies against activating NKRs. The Ifng locus is open and available for 
transcription factor binding in NK cells, allowing for constitutive transcription as well as rapid 
upregulation of expression upon activation (6-8). NK cell activation leads to translation of the pre-
existing pool of Ifng mRNA, the translation of which is regulated by binding of microRNAs, long 
noncoding RNAs, and regulatory proteins to the untranslated region (9). During infection with 
MCMV, IFN-g production is stimulated by the systemic release of inflammatory cytokines such 
as IL-12 and peaks around 36-48 hours post-infection (Fig. 1.1)(10, 11). 
Regulation of NK cell killing 
NK cell killing is a highly-regulated process, reviewed in (12). The first step is forming an 
“immunological synapse” with the target cell. Target recognition is regulated by the balance 
between signaling through activating NKRs recognizing stress-induced or pathogen-encoded 
ligands, and inhibitory receptors recognizing self-MHC. Downregulation of self-MHC due to 
malignancy or viral infection makes cells more susceptible to killing by NK cells. Next, NK cells 




the microtubule and actin networks of the cell. NK cell granules contain cytotoxic proteins such 
as perforin and granzymes, which can enter target cells and cause apoptosis; components of these 
granules are upregulated by stimuli such as IL-15 to boost NK cell cytotoxicity (13). Finally, 
granules are released onto the target, and the NK cell detaches from the dying cell to seek new 
targets. Disruptions to the signaling and/or cytoskeletal movements required for directed target 
cell killing effectively inhibits NK cell killing (14). During MCMV infection, one ligand that 
induces killing of infected cells is the MCMV-encoded protein m157, which is recognized by the 
NKR Ly49H (15). This receptor is present in mice of the C57BL/6 genotype and allows NK cells 
to specifically recognize MCMV-infected cells, enhancing their resistance to the virus (15). Killing 
of infected cells occurs early during infection, but cytotoxic function is boosted as infection 
continues by increasing levels of cytotoxic proteins like granzyme B (Gzmb) (Fig. 1.1)(13). 
Regulation of NK cell proliferation 
NK cell proliferation can occur through both NKR and cytokine stimulation. In vitro NK 
cell expansion was first described in response to high concentrations of IL-2, creating highly 
activated “lymphokine-activated killer cells” (16). IL-15, which is similar to IL-2 but more NK-
specific, also causes proliferation and activation at high doses in vitro and in vivo (17, 18). 
Additionally, exposure to the inflammatory cytokines IL-12 and IL-18 causes subsequent 
proliferation by NK cells after adoptive transfer into mice (19). The extent of NK cell proliferation 
can be controlled by the concentration of cytokine.  
Activating receptor-driven proliferation has been described in vitro with stimulation 
through ligation of NKRs such as NK1.1 and Ly49H, in conjunction with low levels of supportive 
cytokines (20, 21). In vivo proliferation driven by Ly49H is well-studied; although inflammatory 




proliferate at higher rates than Ly49H- NK cells in response to exposure to m157 (Fig. 1.1) (11). 
Finally, NK cells have been described to expand homeostatically in lymphopenic mice, although 
the exact mechanism for this expansion is not completely understood (22, 23).  
 
Figure 1.1. NK cell functions during MCMV infection. After intraperitoneal injection of MCMV, infected cells 
express the MCMV-encoded protein m157. Dendritic cells (DCs) sense pathogen-associated molecular patterns and 
produce systemic inflammatory cytokines such as IL-12 and IL-18, which non-specifically activate NK cells to 
produce IFN-g at 36-48 hours post-infection. The m157 ligand is recognized by a subset of NK cells that express the 
Ly49H activating receptor, leading to preferential killing of infected cells by Ly49H+ NK cells throughout the course 
of infection, and preferential expansion of the Ly49H+ NK cell population between 4-7 days post-infection. 
 
In summary, NK cells are critical for the initial response to viral infection and malignant 
transformation. They can be stimulated by activating receptors or by inflammatory cytokines, and 
in turn produce cytokines and kill non-self or compromised cells. Certain types of stimulation can 

























































interact with and are regulated by metabolism. MCMV infection induces all of these responses and 
provides a well-characterized, clinically-relevant system to study metabolism. 
 
1.2 Metabolic Regulation of Immune Cells 
The field of immunometabolism examines how changes in metabolic pathway usage 
regulate and are regulated by immune cell activation and function. Significant progress has been 
made in elucidating the importance of metabolism for the development, differentiation, activation, 
effector function, and/or memory formation of murine B & T lymphocytes, macrophages, dendritic 
cells (DCs), and even neutrophils. Here, we will review the regulation of non-NK immune cell 
types by glycolysis and oxidative phosphorylation in order to describe possible mechanisms by 
which NK cells might be regulated by metabolism. 
1.2.1 Major Metabolic Pathways 
The two main energy-generating pathways in a cell, glycolysis and oxidative 
phosphorylation (OXPHOS), are often used in concert in resting cells, but can be regulated 
independently to fuel specific functions (Fig. 1.2). The main fuel for most cells is glucose, which 
is processed by glycolysis into pyruvate, high-energy electrons carried by NADH, and 2 molecules 
of ATP. The rate of glycolysis is regulated by diverse signals including the cell’s energy balance, 
the abundance of downstream intermediates, and cell signaling events (24). Several metabolic 
regulators, including mTOR, HIF-1α, and c-myc (Fig. 1.3), increase the rate of glycolysis through 
upregulation of glycolytic enzymes and/or glucose transporters (25). Aerobic glycolysis, or 
fermentation of pyruvate into lactate in the presence of oxygen, is a distinguishing feature of 




fermentation is required to restore the pool of NAD+ from NADH so glycolysis can continue. 
Glucose can be diverted from glycolysis into the pentose phosphate pathway for regeneration of 
the reducing agent NADPH and nucleotide synthesis (28), or glycosylation of proteins for their 
correct folding, function, and expression (29). 
 
Figure 1.2: Major metabolic pathways and programs in immune cells. (Left) Naïve immune cells use glucose to 
fuel glycolysis, producing ATP and pyruvate. Pyruvate is converted into acetyl-CoA, enters into the mitochondria, 
and is processed by the TCA cycle into high-energy electrons. Carriers bring these electrons to the electron transport 
chain for OXPHOS, which requires oxygen to synthesize large amounts of ATP. (Center) In activated effector cells, 
e.g. Th1 and inflammatory macrophages, glycolysis is highly upregulated without concomitant increase in OXPHOS, 
leading to the production of lactate. Metabolites are shunted toward nucleotide synthesis in T cells, ROS/nitric oxide 
in macrophages, fatty acid synthesis in DCs, and antibody production in plasma cells. Depleted TCA intermediates 
can be replaced by glutamine. OXPHOS may function at a low level in activated effector cells. (Right) Tolerogenic 
macrophages, regulatory T cells, and memory T cells downregulate glycolysis, instead oxidizing lipids to fuel the 
TCA cycle. Increased mitochondrial mass leads to greater respiratory capacity and increased OXPHOS. 
 
Pyruvate from glycolysis is converted into acetyl-CoA to enter into the tricarboxylic acid 
(TCA) cycle (Fig. 1.2). The TCA cycle occurs in the mitochondria and processes acetyl-CoA into 
CO2 and high-energy electrons. It contains multiple entry and exit points into other metabolic 
pathways, and can be fueled by glycolysis or fatty acid oxidation (FAO). TCA intermediates such 
as citrate can be used for several biosynthetic reactions, including fatty acid and amino acid 




toward biosynthesis and away from OXPHOS is critical in fueling various immune cell functions. 
Acetyl-CoA is required for acetylation, which can also regulate metabolism directly by promoting 
degradation of metabolic enzymes, as well as indirectly affect the transcription of many genes 
through acetylation of histones, which allows greater chromatin accessibility (29). 
Figure 1.3. Metabolic regulators. A selected list of metabolic regulators important in upregulating glycolysis or 
oxidative metabolism and a brief description of their function. 
 
Conversion of the high-energy electrons produced by glycolysis, FAO, and the TCA cycle 
into energy in the form of ATP occurs during OXPHOS, which takes place in the mitochondria 
(Fig. 1.2). A series of enzyme complexes in the inner mitochondrial membrane, the mitochondrial 
electron transport chain (ETC)(Fig. 1.4), converts these electrons into a H+ gradient that fuels ATP 
synthesis (31). Complexes I and II accept electrons from carriers such as NADH and transport 
them through Complex III to Complex IV, which fixes them to O2 to produce H2O. The energy 
stored in these electrons is used by Complexes I, III, and IV to transport H+ ions across the inner 
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(ATP synthetase) for energy to produce ATP. OXPHOS of electrons from processing one molecule 
of glucose produces around 30 ATP molecules, making it much more efficient than anaerobic 
glycolysis. Reactive oxygen species (ROS) are also generated, especially by Complexes I and III, 
and can cause phosphorylation-like post-translational modifications that modify signaling 
cascades in the cell (32-34). Excess ROS induce damage and the oxidative stress response. Major 
upregulators of oxidative function include AMPK, PPARg, and PGC-1a (Fig. 1.3)(35, 36).  
 
 
Figure 1.4. Mitochondrial electron transport chain. High energy electrons are carried by NADH to Complex I, and 
are passed through Complex II, coenzyme Q (CoQ), Complex III, and cytochrome c, before they are fixed to oxygen 
in Complex IV. Transfer of electron generates reactive oxygen species (ROS) from Complexes I and III, and powers 
hydrogen ion transport. Transport of hydrogen causes a gradient across the inner mitochondrial membrane that is 
converted to energy in the form of ATP by Complex V. 
 
In summary, the two energy-generating pathways—glycolysis and oxidative 
phosphorylation, linked by the TCA cycle—are the center of cellular metabolism. It has been 
described in multiple immune cell types that glycolytic and oxidative metabolism are counter-
regulated to produce inflammatory versus tolerogenic/memory cell types, respectively (Fig. 1.2). 
However, the reasons for the preference for one pathway over another, and the exceptions to this 
generalization, differ between cell types. Findings in these diverse immune cells provide a basis 




1.2.2 Metabolic Regulation in T cells 
 T cells, especially CD8+ T cells, are developmentally and functionally related to NK cells. 
Many of the same regulatory mechanisms exist in both cell types, although NK cells activate much 
more quickly than T cells and form less durable memory, which creates a different set of metabolic 
requirements for function. Given those caveats, T cell immunometabolism provides a basis for our 
understanding of NK cell metabolism. 
T cell activation induces aerobic glycolysis and releases enzymatic repression of IFN-γ 
Naïve murine T cells are relatively metabolically quiescent, and primarily rely upon 
glucose or fatty acids to fuel energy production through OXPHOS (25). T cells upregulate aerobic 
glycolysis following activation through their T cell receptor (CD3) and CD28 (37-39). Although 
aerobic glycolysis is not strictly required for T cell activation (40), it is thought to assist in the 
rapid proliferation of T cells by shunting glucose toward production of biosynthetic precursors 
needed for proliferation, including nucleotide precursors, amino acids, and fatty acids for lipid 
membranes (41, 42). Activating signals such as IL-2 promote the switch to glycolysis by 
upregulating mTOR, c-myc, and other metabolic regulators (25). Increased glycolytic flux also 
encourages differentiation into inflammatory effector cells, i.e. Th1, Th2, or Th17 cells, while 
blockade of glycolysis or mTOR promotes regulatory T cell (Treg) differentiation (25).  
It was recently shown that the glycolytic enzyme GAPDH directly affects IFN-γ expression 
in murine CD8+ T cells by binding to and preventing translation of IFN-γ transcript (40). Increased 
glycolysis after activation sequesters GAPDH, allowing for efficient translation of IFN-γ. Thus, 
increasing the rate of glycolysis not only enhances the ability of activated T cells to proliferate, 





OXPHOS is required for T cell signaling, and is enhanced in regulatory and memory T cells 
OXPHOS is important for T cell activation via generation of ROS. TCR signaling induces 
mitochondrial and cytoplasmic ROS (32, 33), which can activate several signaling pathways (34). 
Loss of the Complex III subunit RISP, and the associated decrease in ROS production, inhibits 
proliferation of murine CD8+ cells (32). On the other hand, overexpression of the ETC assembly 
factor LEM increases ROS and enhances effector functions, including cytokine production and 
proliferation (43).  
The ability to upregulate OXPHOS and decrease glycolysis is also important for the 
generation of Tregs and memory T cells (25, 44). In fact, inhibition of the pro-glycolytic regulator 
mTOR in mice causes differentiation of Tregs in the absence of Treg-polarizing cytokines (45). 
However, mTOR-driven lipid biosynthesis is required for some aspects of normal Treg function, 
such as expression of immune checkpoint blockade receptors (46). Thus, generation of regulatory 
T cells involves downregulation of glycolytic pathways that would lead to more inflammatory 
phenotypes, but Treg function requires balanced usage of different metabolic pathways. 
Peripherally-generated regulatory T cells are also responsive to metabolites produced from the diet 
and microbiota as part of their role in maintaining oral tolerance (44), meaning their regulation by 
metabolism is especially complex. 
Memory CD4+ and CD8+ T cells have greater mitochondrial mass and are highly oxidative, 
which is thought to support longevity and enhanced function during reactivation (47-49). 
Disruption of FAO in murine T cells decreases the number of memory CD8+ T cells, their survival, 
and their ability to produce IFN-γ upon re-stimulation (50), while suppression of mTOR and 
glycolytic metabolism encourages development of memory (51). Increased expression of LEM 




This is not to say that memory T cells only rely on oxidative metabolism—re-activation of memory 
CD8+ T cells is associated with elevated glycolytic rates compared to naïve T cells (52). 
In summary, work in T cells has shown that T cell activation induces aerobic glycolysis 
and accessory pathways leading to the production of macromolecules for proliferation. This 
increase in glycolysis also releases GAPDH-mediated suppression of IFN-g production, providing 
a fascinating example of direct regulation of immune function by metabolic enzymes. On the other 
hand, generation of regulatory and memory T cells is promoted by oxidative metabolism, and the 
enhanced lifespan and increased reactivity of memory T cells is linked to an increased number of 
mitochondria. Whether NK cell IFN-g production is regulated by GAPDH, and whether changes 
similar to those in T cells fuel MCMV-adapted “memory” NK cells, are currently unknown or 
under investigation. 
 
1.2.3 Metabolic Regulation in Macrophages 
 Macrophages are non-proliferative phagocytes. Their metabolism is relatively well-
studied, and provides a model for regulation of innate immunity by metabolism. Macrophages and 
T cells both adhere to the core paradigm in immunometabolism: that inflammation is associated 
with aerobic glycolysis and tolerance is associated with oxidative metabolism. 
Inflammatory macrophages use aerobic glycolysis to produce NO and other defense molecules 
Initial differentiation of circulating monocytes into macrophages is correlated with 
becoming more oxidative and less glycolytic, and macrophages remain oxidative at baseline (53, 
54). Similar to T cells, proinflammatory (classically-activated or M1) macrophages switch to 
aerobic glycolysis upon activation with LPS (53, 55). This metabolic reprogramming is mediated 




decreasing signaling of the energy sensor AMPK, and activating shunt pathways (Fig. 1.3). Rather 
than use TCA intermediates for production of ATP through OXPHOS or to build biomass for 
proliferation, as macrophages do not proliferate, LPS-activated macrophages use TCA 
intermediates to produce pathogen defense molecules (56, 57). Specifically, citrate is used to 
produce NADPH and arachidonic acid, which are converted into nitric oxide (NO), ROS, and 
prostaglandins (56). NO directly inhibits the ETC Complexes I and IV to further decrease the rate 
of OXPHOS (58). Additionally, secretion of the inflammatory cytokine IL-1b is tied to the rate of 
glycolysis on two levels. First, production of the metabolite itaconate by activated macrophages 
inhibits Complex II and increases the level of succinate (59, 60). Succinate then stabilizes HIF-
1a, which increases the rate of glycolysis, increases mitochondrial ROS production, and enhances 
pro-IL-1b transcription (61, 62). Second, splicing of pro-IL-1b protein into its active form by the 
NLRP3 inflammasome requires glycolysis in an unclear mechanism (63).  
After activation, macrophages appear to shift back to oxidative metabolism, possibly as a 
mechanism to limit inflammation. Work in the human monocyte cell line THP-1 has shown that, 
after activation with LPS, THP-1 cells are highly glycolytic during early responses, then return to 
primarily using oxidative metabolism. This was linked to changes in the NAD+/NADH redox 
balance governed by activity of sirtuins that sense NAD+ levels and alter HIF-1a and PCG-1a 
activity to control glycolytic and fatty acid metabolism, respectively (64). Whether this return to 
normal metabolic state after activation occurs in monocytes and macrophages in vivo is not known. 
Tolerogenic macrophages maintain oxidative metabolism 
While inflammatory macrophages have “broken” their TCA cycles in order produce 
reactive oxygen and nitrogen species, tolerogenic (alternatively-activated or M2) macrophages 




LPS-activated macrophages (53, 65). Compared to inflammatory macrophages, opposite 
regulatory pathways are induced in tolerogenic macrophages: AMPK rather than mTOR, HIF-2a 
rather than HIF-1a, PFKFB1 (“slow glycolysis” enzyme) rather than u-PFK2, and Arginase-1 
rather than nitric oxide synthase (both compete for arginine) (65, 66). This is reflected functionally 
in decreased production of IL-1b and NO, and increased production of the tolerogenic cytokine 
IL-10. It appears that tolerogenic macrophages, like regulatory T cells, have significantly 
downregulated their glycolytic rate and rely primarily on oxidative metabolism.  
“Trained immunity” is associated with aerobic glycolysis 
While innate immunity is not typically considered to have memory, several memory-like 
features have been described that boost function in innate cells upon re-exposure to a pathogen. 
For example, human monocytes exposed to b-glucan for 24 hours, then rested for seven days, have 
greatly increased cytokine production when exposed to various pathogenic ligands. “Trained 
immunity” is associated with downregulation of mitochondrial function and increased levels of 
aerobic glycolysis (67), and is linked to mTOR and HIF-1a signaling as well as epigenetic 
changes. This is very different from T cell memory, which is associated with an oxidative state 
that likely allows T cell memory to persist for much longer than trained immunity. 
In summary, LPS induces inflammatory macrophages which undergo aerobic glycolysis in 
order to use TCA intermediates for the production of reactive oxygen and nitrogen species, which 
in turn inhibit OXPHOS. On the other hand, IL-4 induces tolerogenic macrophages that maintain 
oxidative function. Unlike T cell memory, macrophage “trained immunity” is associated with a 
glycolytic phenotype and lower mitochondrial function. It is not known whether NK cell activation 
and “memory” are more similar metabolically to macrophage rapid activation and “trained 




1.2.4 Metabolic Regulation in Dendritic Cells 
Dendritic cells (DCs) present antigen to T cells and are major producers of inflammatory 
cytokines, many of which NK cells respond to. As NK cells are a major producer of the cytokine 
IFN-g early in viral infection, it is possible that some of the metabolic changes required to generate 
cytokines in DCs are present in more subtle forms in NK cells. 
Increased glycolytic flux fuels fatty acid synthesis in activated dendritic cells 
In general, DCs use fatty acids to fuel OXPHOS at rest, but increase glucose consumption 
and glycolytic rates within minutes of activation through TLRs (68-70). Increased glycolytic flux 
is thought to aid rapid cytokine synthesis by increasing citrate levels for fatty acid synthesis (FAS), 
which fuels expansion of the endoplasmic reticulum (ER) and Golgi complex membranes (53, 71). 
Studies have also shown that proper antigen presentation requires appropriate control of lipid 
metabolism and autophagy, though lipid accumulation by DCs can be activating or suppressing 
depending on the context (35, 72). It is thought that the initial increase in glycolysis during 
activation is dependent on an unusual pathway of AKT signaling, and only later are more 
conventional mTOR and HIF-1a pathways engaged to maintain elevated glycolysis (35). mTOR 
signaling has also shown to be required for production of several immunogenic as well as 
tolerogenic cytokines in DCs. Functionally, metabolic changes divide DC activation into early and 
late states, and different types of DCs have different requirements. 
Metabolism of activated DCs varies depending on source and function 
DCs can differentiate from several types of precursors, with a range of ability to activate  
the immune system (immunogenicity). After prolonged activation (12h), murine bone marrow-
derived DCs (BMDCs) rely exclusively on aerobic glycolysis, as BMDC production of NO inhibits 




upregulate glycolysis and decrease OXPHOS upon activation (70), though they do not produce 
NO and so maintain some OXPHOS function. On the other hand, human monocyte-derived DCs 
(moDCs) have increased mitochondrial and oxidative function through increased expression of 
PPARg and PGC-1a (35, 74). The findings in cytokine-secreting plasmacytoid dendritic cells 
(pDCs) are mixed. Human pDCs stimulated with toll-like receptor 7 (TLR7) agonists and RNA 
viruses upregulate glycolysis during activation (75), while pDCs stimulated through TLR9 
primarily use FAO and OXPHOS for function (76).  
DC immunogenicity can be downregulated by metabolites acquired through the diet or 
microbiota, similar to sensing by regulatory T cells. Butyrate, oxysterols, ATP, and lactate all 
decrease DC immunogenicity via decreased antigen presentation, decreased production of 
inflammatory cytokines, and increased production of anti-inflammatory cytokines like IL-10 (35). 
In this way, DCs tune the immune response based on the extracellular metabolic environment. 
In summary, DCs upregulate glycolysis after TLR activation to fuel fatty acid synthesis. 
Fatty acids are used to expand organelles used for secretion of cytokines, and affect regulation of 
antigen presentation. Different types of DCs use a range of metabolic strategies, from NO-
producing DCs that rely completely on aerobic glycolysis to more oxidative moDCs. Whether or 
not NK cell cytokine synthesis, especially in activated NK cells that are primed for increased 
cytokine production, is associated with expansion of the secretory organelles is unknown. 
1.2.5 Metabolic Regulation in B cells 
While B cells are similar in many ways to T cells, antibody-producing plasma cells are a 
unique case. The exaggerated phenotype of plasma cells displays some of the metabolic 
adaptations required for massive protein production, which may be present in less extreme form 




B cell activation upregulates both glycolysis and OXPHOS 
Naïve B cells are metabolically quiescent, which is maintained by GSK3 signaling (77). 
Their activation through the B cell receptor is accompanied by increases in both glycolysis and 
OXPHOS, with less aerobic glycolysis than in T cells (78-80). Upregulation of glycolysis has been 
linked to signaling through protein kinase C beta (PKCb) (81) and mTOR. Activated B cells can 
become short-lived plasma cells that secrete antibody immediately, or migrate to the germinal 
center (GC) to undergo class switch recombination (CSR) and somatic hypermutation, eventually 
forming memory B cells or long-lived plasma cells. The GC is a resource-limited space in which 
B cells rapidly proliferate, providing unique metabolic challenges. Low oxygen availability may 
combine with c-myc and HIF-1a activation to drive aerobic glycolysis and increase fuel uptake 
for proliferation (80). However, GC B cells are also noted to have higher mitochondrial mass than 
naïve B cells (77). B cell fate upon exit from the GC has been correlated with the amount of 
mitochondria and ROS production, as well as the amount of mTOR signaling, with memory cells 
generated from the more mitochondrially-active subset (82).  
Plasma cells fuel antibody production using fatty acids for secretory organelles and glucose for 
glycolysation 
An extraordinary metabolic transformation occurs when B cells become plasma cells, 
which secrete thousands of antibodies per second. Transformation from an activated B cell into a 
plasma cell requires growing the ER and Golgi membranes to support antibody production, which 
requires a switch to fatty acid synthesis pathways as in DCs (83). Interestingly, OXPHOS appears 
to be maintained, suggesting that citrate (the major fuel for FAS) is replenished by glycolysis and 
glutaminolysis (84). There is some evidence that plasma cells in the gut also take up fatty acids 




(85). Mature plasma cells have also greatly increased their uptake of amino acids and signaling 
through mTOR to support protein synthesis. Plasma cells have an unusual requirement for glucose, 
some of which fuels energy production but most of which appears to fuel antibody glycosylation 
(86). Increased mitochondrial function and the ability to use glucose to fuel OXPHOS is associated 
with the increased longevity of long-lived plasma cells compared to short-lived plasma cells (86). 
In summary, B cells upregulate both glycolysis and OXPHOS after activation, but 
becoming an antibody-secreting plasma cell requires a completely different metabolic profile 
dedicated to supporting antibody production. Like plasma cells, NK cells may require glucose 
metabolism for glycosylation of proteins, although at lower levels than in plasma cells. 
 
1.2.6 Metabolic Regulation in Neutrophils 
While neutrophils share few similarities with NK cells, they are included here to provide 
an example of a extreme metabolic phenotype. Neutrophils are the first and primary defense 
against extracellular pathogens, which they kill with a respiratory burst of damaging reactive 
oxygen and nitrogen species. Neutrophils are extremely short-lived cells with relatively few 
mitochondria with low function, and thus mainly use aerobic glycolysis for their function (87). 
Mitochondria do not participate in neutrophil respiratory burst or phagocytosis, but are likely 
involved in neutrophil trafficking and apoptosis (88, 89). The requirement for aerobic glycolysis 
in neutrophils is unclear, but may be related to the need to function in hypoxic environments or 
specialization of the mitochondria to induce apoptosis. Neutrophils are able to cast neutrophil 
extracellular traps (NETs) of their DNA into the extracellular space, and this process requires 
glycolysis, glutamine, and cytoplasmic (not mitochondrial) ROS (90, 91). In summary, 




their survival and function. One hypothesis is that reliance on aerobic glycolysis decreases 
longevity due to the metabolic strain it places on the cell; this is likely the case in neutrophils, and 
may be relevant in NK cells.  
 
1.3 Metabolic Regulation in NK cells 
 Compared to what is known in T cells, macrophages, and DCs, less is known about 
metabolic regulation in NK cells. While they are most developmentally and functionally similar 
to CD8+ T cells and thus might be expected to be similarly metabolically regulated, they also share 
some features of the myeloid cells of the innate immune system in their quick reaction time from 
activation to effector function. We are particularly interested in the role of glycolytic and oxidative 
metabolism in regulating NK cell function. 
NK cell development requires mTOR signaling 
Several recent in vitro and in vivo studies have found that IL-15 signals through 
PI3KàAKTàmTOR to allow for murine NK cell development and survival, as well as for 
priming NK cells for enhanced activity (92-94). mTOR activity is required for proliferation of 
immature NK cells in wildtype mice, so mice with NK-specific deletion of Mtor have very few 
circulating NK cells. Any surviving NK cells are immature, with decreased proliferative capability 
and slower/lower production of Gzmb (92). While the role of mTOR signaling in NK development 
has been described, it is not well understood which of these changes are due to mTOR’s alteration 
of the rate of glycolysis compared to its other effects on cell growth; this is an area in which more 
targeted inhibition of glycolytic pathways may provide additional insight. While mTOR is required 




metabolism. Naïve murine splenic NK cells rely on glucose-driven OXPHOS at baseline, similar 
to resting T cells (95). 
IFN-γ production by naïve NK cells requires glycolysis and OXPHOS if activated by receptors, 
but not cytokines 
Stimulation for 6 hours with either cytokines or NKR ligation is not accompanied by 
significant changes in flux through the glycolytic or OXPHOS pathways, as demonstrated by 
extracellular flux assays of glycolysis (measured as extracellular acidification rate, ECAR) and 
OXPHOS (measured as oxygen consumption rate, OCR) (Fig. 1.5)(95, 96). However, flux through 
glycolysis and OXPHOS is required for NK cell IFN-γ production within this time period. 
Interestingly, there is a difference in the metabolic requirements when NK cells are stimulated 
through NKRs versus cytokines (95). IFN-γ production stimulated through the NK1.1 or Ly49D 
receptors is almost completely blocked by glucose deprivation or OXPHOS inhibition (Fig. 1.6).  
 
 
Figure 1.5: Increased rates of metabolism with prolonged IL-15 exposure but not short-term activation. Short-
term activation (6 hours) by NKRs or cytokines does not change the rates of glycolysis or OXPHOS, despite 
production of IFN-γ and degranulation.  Culture with IL-15 for at least 18 hours in one studies and 3 days in another 
increases both glycolysis and OXPHOS, with a greater enhancement of glycolysis. These IL-15 “primed” NK cells 




However, IFN-γ produced downstream of IL-12 + IL-18 signaling is not susceptible to inhibition 
of OXPHOS (Fig. 1.6), or deprivation of most metabolic fuels (glucose, glutamine, fatty 
acids)(95). Thus, IFN-γ production induced by IL-12+IL-18 appears to be relatively metabolism-
independent, and these findings suggest there might be significant flexibility in the fuels that NK 
cells utilize to assist with production of IFN-γ. This is in contrast to T cells, in which glycolysis is 
required for IFN-γ production in response to both receptor stimulation and IL-12+IL-18 (40, 97). 
It is not clear why stimulation by NKRs versus cytokines leads to dramatically differential 
metabolic requirements in NK cells, and this is an area of active investigation in our lab. The 
requirement for OXPHOS in NKR-activated NK cells is unlikely to be due to a lack of ROS, as 
supplementation with H2O2 did not rescue IFN-γ production under OXPHOS inhibition (95). 
Additional studies, both in vitro and in vivo, are needed to find the differences between NKR and 
cytokine activation pathways that allow one, but not the other, to be regulated metabolically. 
To summarize, naïve murine NK cells use OXPHOS, consistent with findings in other 
resting immune cell types, and do not require significant changes in metabolism during short-term 
function. However, activation of NK cells is regulated by metabolism in a stimuli-specific manner. 
Why NKR activation requires flux through glycolysis and OXPHOS, while cytokine activation 
does not, is not known and likely represents a novel mechanism for metabolic control of immune 
function. Examining metabolic regulation of other NK cell functions that can be induced by both 
NKR and cytokine signaling, such as proliferation, will help us better understand this phenomenon. 
IL-15 priming changes the basic metabolism of NK cells  
We and others have observed significant upregulation of glycolysis and OXPHOS after 





Figure. 1.6. Naive NK cells require OXPHOS for receptor-stimulated IFN-g production, but activation with IL-
15 eliminates this requirement. Fresh murine splenic NK cells (top and middle) or IL-15-activated “primed” NK 
cells (bottom, 72hr stimulation with 100ng/ml IL-15) were activated with IL-12/18 (top) or plate-bound anti-NK1.1 
(center and bottom) in the presence or absence of the ATP synthetase inhibitor oligomycin (100nM). NK cell 
production of IFN-g protein was measured after 6 hours. % of IFN-g+ NK cells shown. 
multiple cell types and supports NK cell differentiation, survival, proliferation, and cytotoxicity 
(98, 99). At low doses (1-10ng/ml), IL-15 promotes the survival of NK cells in vitro, while high 
dose (100ng/ml) IL-15 induces proliferation and increased cytotoxicity, but does not cause 
degranulation or IFN-g production (95). After 18h culture with high-dose IL-15, NK cells 
significantly increase maximal respiratory capacity and basal OCR and ECAR (92). Longer (72-
120h) culture in high-dose IL-15 increases both ECAR and OCR, with a decreased OCR:ECAR 
ratio, suggesting a greater reliance on glycolysis (Fig. 1.5)(92, 95). This parallels findings in T 
cells, in which several days of activation induces a transition to aerobic glycolysis.  
Upregulation of glycolysis after activation in T cells has been attributed to the activity of 




mTOR signaling in NK cell function has recently to attention. In vitro studies using the mTOR 
inhibitor rapamycin have shown that mTOR signaling downstream of IL-15 is required for optimal 
NK cell IFN-g and Gzmb production, as well as NK cell proliferation (93). In vivo studies 
examining the role of mTOR are covered in the next section, but show that mTOR is necessary for 
normal NK cell antiviral function.  
Extended activation with IL-15 alters not only the baseline metabolism of NK cells, but 
also their metabolic requirements for IFN-γ production. While fresh murine NK cells require both 
OXPHOS and glycolysis for NKR-stimulated IFN-γ production, NK cells primed for at least three 
days in high-dose IL-15 produce IFN-γ in response to receptor stimulation even when OXPHOS 
is inhibited (Fig. 1.5)(95). This effect was not seen in T cells, in which inhibition of glycolysis 
decreased IFN-γ production in T cells stimulated for three days with CD3 + CD28 or IL-12 + IL-
18. (40, 97). These IL-15-primed NK cells are also significantly less susceptible to glucose 
deprivation. This “metabolic priming” was not apparent at <72 hours of stimulation or with low-
dose IL-15, suggesting both time and dose-dependent effects of IL-15 priming. While high doses 
of IL-15 cause robust NK cell proliferation, metabolic priming is not dependent on proliferation, 
as IFN-γ production in both highly- and poorly-proliferated NK cells was similarly resistant to 
OXPHOS inhibition (95). On the other hand, an alternate priming protocol using intermediate-
dose IL-15 (50ng/mL) for seven days found that IFN-γ production in response to 18h stimulation 
with IL-2 + IL-12 is significantly impaired in the presence of glycolytic or mTOR inhibitors (93). 
These results suggest fundamental differences between metabolic regulation T cell and NK cell of 
IFN-g production, and that metabolic requirements may shift depending on the type or length of 
stimulation.  




accompanied by changes in metabolic flux, but priming with high-dose IL-15 leads to upregulation 
of metabolism, specifically enhanced glycolysis. Investigating different routes of activation is 
important to gain insight into how NK cells increase glycolysis and OXPHOS, and what benefits 
this confers. The observation that prolonged activation significantly alters NK cell metabolism is 
particularly relevant to experiments in the literature using IL-2 or IL-15 in vitro-expanded NK 
cells. Caution should be used in interpreting findings from in vitro expanded NK cells and 
extension of those findings to naïve NK cells in vivo that have not been highly primed. 
Additionally, in order to understand how IL-15 alters NK cell metabolism, we need to understand 
how IL-15 reverses metabolic requirements for short-term NK cell activation. Whether this is due 
to increased fuel flexibility, or use of activation pathways that are not metabolically-regulated, is 
unknown. 
Manipulation of murine NK cell metabolism in vivo 
While it is simpler to examine metabolism in vitro, some work has been done examining 
the effect of decreased mTOR signaling on NK cell function in vivo using both drug treatment and 
genetic models. Treatment of mice with inhibitors of mTOR or glycolysis in vivo significantly 
decreases NK cell size, nutrient uptake capacity, and production of IFN-γ 24 hours after activation 
by injection of poly(I:C) (93). In an NK-specific model of Mtor deletion, there is a significant 
decrease in mature, peripheral NK cells despite normal bone marrow numbers (92). Remaining 
NK cells from these mice are immature, likely due to an mTOR-dependent proliferative stage 
during NK cell development. Mtor-deficient NK cells produce IFN-γ normally to short-term NKR 
and IL-12 + IL-18 stimulation, but have some defects in poly(I:C) priming of NKR activation. 
Interestingly, NK cells genetically lacking mTOR have no significant differences in their ability 




to NK cells inhibited by injection of rapamycin, which have decreased IFN-γ production at 1.5 
days post-MCMV infection (94). It is difficult to compare these two studies, since Mtor-deficient 
NK cells are immature and present at a much lower frequency. These studies also highlight the 
potential for discrepancies between drug-based, non-specific inhibition strategies and genetic 
models; differences may also be due to differences in the kinetics of mTOR inhibition, or off-
target effects of drug treatment. 
In summary, much of the in vivo work in mouse models has focused on the key role of 
mTOR signaling in NK cell development, function, and responses to MCMV. Although mTOR 
signaling upregulates glycolytic metabolism, mTOR signaling and glycolysis likely have separate 
but overlapping roles in regulating NK cell function. This possibility deserves further 
investigation. Careful experimentation may reveal that for some of these functions, upregulation 
of glycolysis may be sufficient to cause the changes attributed to mTOR signaling, while for other 
functions, additional metabolic regulators or pathways may be required. Further work needs to be 
done to better understand the role of both glycolytic and oxidative metabolism during viral 
infection, and better models that are more specific and allow maturation of NK cells need to be 
developed to do it. 
Metabolic requirements in human NK cells 
Ideally, the knowledge we gain through murine models of NK cell regulation are applicable 
to human cells. A recent study demonstrated that human peripheral blood NK cells have metabolic 
requirements similar to murine NK cells, despite differences between human and murine NK cells. 
One key distinction is that the expression of CD56 in humans is linked to maturation, and 
distinguishes less mature, cytokine-producing CD56bright NK cells from more mature, cytotoxic, 




differed between the two groups. CD56bright NK cells were more glycolytic and had increased 
metabolism after stimulation compared to CD56dim cells, suggesting either developmentally-
regulated differences in metabolism, or perhaps that cells more focused on cytokine synthesis 
require increased metabolic capacity compared to cells focused on killing. 
Similar to murine NK cells at rest and after IL-15 priming, human NK cells have relatively 
low metabolism at rest, but significantly increase glycolysis and OXPHOS after 18h of stimulation 
with IL-2 or IL-12 + IL-15 (101). Inhibition of mTOR in human NK cells significantly inhibits the 
ability of IL-2 alone to upregulate glycolysis, but glycolytic upregulation with IL-12+IL-15 is 
unchanged (101). The fact that mTOR is required for IL-2- but not IL-12+IL-15-driven glycolysis 
in human NK cells is intriguing since IL-2 and IL-15 use the same signaling receptors. These 
results suggest that IL-12 signaling might drive increased glycolysis in an mTOR-independent 
fashion.  
Human NK cells also have specific metabolic requirements for IFN-γ production. 
Inhibition of OXPHOS using oligomycin decreases IFN-γ production in response to IL-12+IL-15 
(101), but has no effect on the small quantity of IFN-g produced in response to IL-2 alone (95). 
The opposite phenotype is true with mTOR inhibition. Limiting the rate of glycolysis by culturing 
cells in the presence of galactose rather than glucose leads to decreased IFN-γ production by 
CD56bright NK cells in response to IL-12+IL-15 (101), although the effect of direct glycolytic 
inhibition is unknown. Other functions of NK cell activation, such as degranulation or upregulation 
of CD69 and GzmB, are not affected by rapamycin, galactose, or oligomycin, with the exception 
that oligomycin inhibits degranulation in the more cytotoxic CD56dim NK cells. It is not yet clear  





In summary, work examining metabolic regulation in human NK cells has just begun. IFN-
g production is regulated by glycolysis, OXPHOS, and mTOR signaling, as in murine NK cells. 
Metabolic differences in CD56dim and CD56bright populations reflect their disparate roles as 
cytotoxic vs. cytokine-producing subsets, but additional investigation is required understand how 
differences in metabolism between the two groups fuels differential function. 
 
1.4 Conclusions and Aims 
Several recent studies have demonstrated that glycolysis, OXPHOS, and mTOR signaling 
are important for mouse and human NK cell activity. In general, metabolic “reprogramming” upon 
activation to use aerobic glycolysis is associated with production of biomass for proliferation and 
shunting of glycolytic and TCA intermediates toward biosynthetic pathways for specific effector 
functions. On the other hand, downregulation of glycolysis and reliance on oxidative metabolism, 
with high mitochondrial function, is associated with long-lived tolerogenic and memory 
phenotypes. However, the interactions between metabolic pathways and effector functions are 
complex, and do not always follow this paradigm. Metabolic requirements for NK cell function 
are dependent on the specific stimuli used, the length of stimulation, and the activation status of 
the NK cell.  
Our major interest is in understanding how NK cells are regulated by metabolism. There is 
a significant body of work examining the role of metabolism in regulating NK cell IFN-g 
production, but less examining NK cell cytotoxicity and proliferation. While work is proceeding 
in examining NK cell metabolism in a variety of culture systems, it has been technically 
challenging to investigate NK cell metabolism in vivo. Cell microenvironments are more difficult 




genetic knockout models can lead to loss of viable NK cells to study. Since the study of metabolism 
in vivo is necessary to investigate more complex functions such as response to viral infection, and 
due to the non-physiological conditions of most in vitro assays, more in vivo research is needed. 
In my dissertation work, I develop both a drug treatment and a genetic model to manipulate 
metabolism in NK cells, with the hope that characterization of these models will be a starting point 
for more tools for in vivo manipulation of metabolism. 
I am focused on the two central energy-generating pathways of the cell: glycolysis and 
oxidative phosphorylation. These have been shown to be counter-regulated in other cell types, 
especially CD8+ T cells which are closely related to NK cells. However, NK cells are different 
than T cells—they activate more quickly, and are not built for longevity. Thus, I was interested in 
how NK cells might diverge from the paradigm found in T cells, and what clues that might reveal 
on the properties that make NK cells unique. While recent work has shown that mTOR plays a 
critical role in NK cell development, activation, and response to viral infection, it is unclear if this 
is due to mTOR’s upregulation of glycolysis or its other functions. While some work has been 
done examining the roles of glycolysis and OXPHOS in NK cell function, this body of work 
attempts to both deepen and widen our understanding of how these two central pathways affect 
NK cell activation. In summary, I am asking, “How are NK cell antiviral functions regulated 
by glycolysis and oxidative phosphorylation in vivo?” We hypothesize that: 
1. Upregulation of glycolysis is required for maximal NK cell responses during MCMV 
infection, and 
2. Intact oxidative metabolism is required for NK cell antiviral functions that are not 




Application of our findings has the potential to inform development of new protocols for 
NK cell immunotherapy that take into account the metabolic changes NK cells undergo during 
activation. For example, modulation of nutrients or use of inhibitors might enhance formation of 
activated NK cells for cancer adoptive immunotherapy. Continued investigation of the metabolic 
regulation of NK cells will provide valuable insight into regulation of NK cell effector functions, 
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Natural killer (NK) cell activation has been shown to be metabolically regulated in vitro; 
however, the role of metabolism during in vivo NK cell responses to infection is unknown. We 
examined the role of glycolysis in NK cell function during murine cytomegalovirus (MCMV) 
infection and the ability of IL-15 to prime NK cells during CMV infection. The glucose 
metabolism inhibitor 2-deoxy-ᴅ-glucose (2DG) impaired both mouse and human NK cell 
cytotoxicity following priming in vitro. Similarly, MCMV-infected mice treated with 2DG had 
impaired clearance of NK-specific targets in vivo, which was associated with higher viral burdens 
and susceptibility to infection on the C57BL/6 background. IL-15 priming is known to alter NK 
cell metabolism and metabolic requirements for activation. Treatment with the IL-15 superagonist 
ALT-803 rescued mice from otherwise lethal infection in an NK-dependent manner. Consistent 
with this, treatment of a patient with ALT-803 for recurrent CMV reactivation post-hematopoietic 
cell transplant was associated with clearance of viremia. These studies demonstrate that NK cell-
mediated control of viral infection requires glucose metabolism, and that IL-15 treatment in vivo 
can reduce this requirement and may be effective as an antiviral therapy.  
2.2 Introduction 
It is now recognized that metabolism plays a key role in the activation and specialized 
functions of immune cells. Cells fuel ATP production through two major metabolic pathways: 
glycolysis, the metabolic breakdown of glucose, and oxidative phosphorylation, the synthesis of 
ATP in the presence of oxygen. For T cells, macrophages, and DCs, inflammatory activation is 
associated with “metabolic reprogramming” from a relatively metabolically-quiescent to a highly 




precursors for effector functions. For example, high glycolytic flux can produce nucleotide 
precursors for cell division in T cells (5), citrate for production of reactive oxygen species in 
macrophages (6), and lipid precursors for endoplasmic reticulum membrane synthesis in DCs (7). 
Glycolytic enzymes have also been shown to directly regulate cytokine production and gene 
expression in T cells (8, 9). Thus, in many immune cell types, metabolic regulation equips 
activated cells to carry out specialized functions.  
NK cells are innate cytotoxic lymphocytes that are the first responders against virally-
infected and tumor cells. They respond within hours of stimulation by releasing cytokines, such as 
IFN-γ, and killing target cells. Stimulation with cytokines for longer periods, including 
inflammatory cytokines such as IL-12 and IL-15, significantly enhances NK cell functions. Recent 
studies have demonstrated that certain NK cell responses require metabolic cues. Naïve NK cells 
rely on glucose-fueled oxidative phosphorylation, while expansion with IL-15 elevates metabolic 
rates with a preference toward glycolysis, similar to changes seen during the activation of CD8+ T 
cells (10, 11). Several studies show that NK cell production of the cytokine IFN-γ is regulated by 
metabolism (10, 12-14). We previously demonstrated that in freshly-isolated murine NK cells, 
IFN-γ production after short-term receptor activation is highly dependent on glycolytic and 
oxidative metabolism, while IFN-γ production stimulated by cytokine activation (IL-12 + IL-18) 
is independent of both metabolic pathways. We found that receptor activation depends less on 
these metabolic pathways after priming with high-dose IL-15 (10). Others have found that after 
expansion in IL-15 and stimulation with IL-2 + IL-12, highly-activated “lymphokine-activated 
killer” (LAK) cells require glycolysis for maximal production of IFN-γ and the cytotoxic granule 
protein granzyme B (Gzmb) (12). Studies in human NK cells show a similar pattern—IFN-γ and 




these studies demonstrate that NK cells have specific metabolic requirements for IFN-γ and Gzmb 
production. Few studies have directly examined the metabolic regulation of other NK cell 
functions such as target killing and proliferation. Here, we investigate the role of glycolysis in NK 
cell cytotoxicity in vitro and in vivo in response to viral infection.  
NK cells are particularly important for antiviral responses against cytomegalovirus. In 
response to human cytomegalovirus (HCMV), NK cells bearing the activating NKG2C receptor 
rapidly expand and persist (15, 16). These cells, termed CMV-adapted NK cells, display enhanced 
responses, particularly when triggered by antibodies through their Fc receptor (17-20). While the 
adaptive T cell response to HCMV is required for long-term immunity, evidence from a B and T 
cell-deficient patient demonstrates that the expansion of NKG2C-positive NK cells alone can 
control HCMV infection (21).  
Acute infection with murine cytomegalovirus (MCMV) in C57BL/6 mice is well described 
to be controlled by NK cells (22-26). During the first 2 days of infection, NK cells are activated 
by circulating cytokines and respond by producing a burst of immunomodulatory cytokines, most 
notably IFN-γ (27). After day 2, expression of the virally-encoded ligand m157 on the surface of 
infected cells leads to the expansion of Ly49H+ NK cells which specifically recognize and kill 
m157-expressing cells (28-31). Thus, this murine system can be used to examine NK cell 
activation, proliferation, and killing of infected cells in vivo, and is a model for human infection.  
In the current study, we found that NK cell proliferation and cytotoxicity following IL-15 
priming in vitro were impaired when NK cells were cultured with the glucose metabolism inhibitor 
2-deoxy-ᴅ-glucose (2DG), which blocks the first two enzymes of glycolysis. Glycolytic inhibition 
decreased expression of cytotoxic proteins and altered the adhesion of NK:target conjugates. In 




infection and was associated with impaired NK-mediated clearance of m157+ targets. Similar 
susceptibility to infection was also observed when animals were treated with rapamycin, a drug 
that inhibits the mTOR pathway. Priming with the IL-15 superagonist ALT-803 rescued 2DG- or 
rapamycin- treated animals from lethal infection. 2DG also decreased human NK cell cytotoxicity, 
and here we describe a hematopoietic cell transplant (HCT) patient with recurrent CMV 
reactivation treated with ALT-803. Similar to findings in our murine model, ALT-803 treatment 
in this patient was associated with clearance of viremia, suggesting therapeutic potential for IL-15 
agonists in CMV. 
2.3 Results 
Inhibiting glucose metabolism with 2DG decreases NK cell proliferation and cytotoxicity in vitro 
Murine NK cells require activation, such as priming with IL-15, in order to upregulate 
cytotoxic effector molecules, such as Gzmb, and effectively kill target cells (32). To investigate 
the requirement for glucose metabolism in NK cytotoxicity, NK cells were purified from wildtype 
C57BL/6 mice and plated in 100ng/mL IL-15 with or without 1mM 2DG for 72 hours. This dose 
of 2DG maintained NK cell viability, with minimal differences between treated and untreated cells 
(Supplementary Figure 2.1A). Extracellular flux assays confirmed that 2DG treatment 
significantly decreased NK cell glycolysis, as measured by the extracellular acidification rate 
(ECAR) (Figure 2.1A). We previously demonstrated that naïve murine NK cells primarily use 
glucose-based oxidative phosphorylation (10). Consistent with this, 2DG treatment also decreased 
the rate of oxygen consumption (OCR) (Figure 2.1A). 2DG significantly inhibited IL-15-induced 
proliferation (Figure 2.1B), leading to a reduction in the number of cells recovered at the end of 





Figure 2.1. Glucose metabolism blockade during activation decreases NK cell proliferation and cytotoxicity. 
Purified NK cells were cultured for 72 hours in 100ng/mL IL-15 without (black) or with 1mM 2-deoxy-ᴅ-glucose 
(2DG, green). A) Representative extracellular flux assay showing glycolytic rate as estimated by extracellular 
acidification rate (ECAR); glycolytic stress test shows baseline ECAR in glucose-free media and after addition of 
glucose, maximal ECAR after addition of oligomycin, and non-glycolytic acidification after 2DG. Summary data 
shows ECAR, oxygen consumption rate (OCR), and the OCR/ECAR ratio normalized to control (n=4/group in 3 
separate experiments, ratio paired t test performed on raw data). B) Representative histogram shows CFSE dilution of 
proliferating NK cells. Summary graph shows the percentage of NK cells proliferated (n=5 experiments, paired t test). 
C) NK cells activated in IL-15 +/- 2DG were assessed for their ability to kill Ba/F3-m157 target cells at different 
effector:target ratios (ratios represent Ly49H+ NK cells:targets), n=8/group, 4 experiments, 2-way ANOVA. Data is 
given as mean +/- SEM. ns=not significant (p≥0.05), *=p<0.05, ***=p<0.001. 
The ability of NK cells to kill target cells after priming with IL-15 +/- 2DG was measured 
at various effector-to-target ratios in complete media. Ba/F3-m157 cells are murine pro-B cells 
ectopically expressing the MCMV-encoded protein m157 that is recognized by Ly49H+ NK cells, 
and killing of Ba/F3-m157 is mediated solely by Ly49H-expressing NK cells (29, 33, 34). Ly49H+ 
NK cells killing of Ba/F3-m157 targets was significantly impaired when activated in the presence 
of 2DG (Figure 2.1C). NK cell killing of MHC class I-deficient RMA-S tumor cells (35, 36) was 
also significantly impaired by 2DG. Interestingly, killing of YAC-1 tumor cells, which are 




These results suggest that glycolytic inhibition caused target-specific deficits in NK cell killing, 
possibly based on different mechanisms of target cell recognition and NK activation. 
Decreased killing by 2DG-treated NK cells is associated with low Gzmb and variable actin 
accumulation during target conjugation 
We investigated several mechanisms by which 2DG might decrease NK cell cytotoxicity. 
First, IL-15 increases levels of cytotoxic granule proteins in NK cells (32). Treatment with 2DG 
reduced expression of Gzmb (Figure 2.2A), suggesting one potential mechanism for decreased NK 
cell cytotoxicity. Next, we investigated the dynamics of NK cell recognition and killing of target 
cells. Target killing is a tightly-orchestrated event comprised of multiple steps including 
recognition of the target cell, adhesion and formation of an immunological synapse (IS), anchoring 
to the target with filamentous F-actin, convergence of granules to the microtubule organizing 
center (MTOC), polarization and trafficking of the MTOC towards the IS, degranulation, and 
finally detachment (40). By flow cytometry, 2DG did not significantly decrease NK cell 
recognition of potential targets, as demonstrated by normal conjugate formation between 2DG-
treated NK cells and Ba/F3-m157 targets at a variety of timepoints (Figure 2.2B). Confocal 
microscopy of co-cultured NK cells and Ba/F3-m157 targets also demonstrated conjugate 
formation by 2DG-treated NK cells (Figure 2.2C). In some conjugates in both treatment groups, 
Ly49H was detected at the synapse (Figure 2.2D). However, actin accumulation at the IS was 
highly variable among 2DG-treated NK cells, indicating that 2DG may impair proper adhesion to 
the target (Figure 2.2C, E). Compared to 2DG-treated NK cells, most control NK cells had neutral 
or positive actin accumulation, indicating abnormal anchoring to the target and commitment to 
killing (Figure 2.2E). However, 2DG did not affect polarization of the MTOC, as measured by the 





Figure 2.2. In vitro treatment with 2DG decreases NK cell production of granzyme B and alters actin 
accumulation at the immunological synapse. Purified NK cells were cultured for 72 hours in 100ng/mL IL-15 with 
or without 1mM 2-deoxy-ᴅ-glucose (2DG). A) Representative flow histogram shows Gzmb levels in naïve (filled) 
and activated NK cells cultured without (black) or with 1mM 2DG (green). Summary data is normalized to MFI of 
naïve NK cells (n=9/group, 5 separate experiments, ratio paired t test performed on raw data). Error bars denote SEM. 
B) NK cells were incubated at a 1:1 ratio with Ba/F3-m157 target cells for various times; conjugates were detected by 
flow cytometry. Representative flow cytometry shows CFSE+, CellTrace Violet (CTV)+ conjugates, and conjugation 
curve shows percentage of CFSE+ cells conjugated (n=2-3 technical replicates, error bars indicate SEM, representative 
of 3 separate experiments). C-F) NK cells were incubated with Ba/F3-m157 cells for 40 minutes at a 2:1 ratio. C-D) 
Fluorescence microscopy of NK:Ba/F3-m157 conjugates show convergence of granules (green = Gzmb, white = Prf), 
Ly49H accumulation at the synapse (yellow), polarization of the microtubule organizing center (MTOC, blue) toward 
the synapse, and actin accumulation (red). Scale bar = 2µm. Representative images for the range of control and 2DG-
treated NK cells are shown. E) Quantification of actin accumulation by area * intensity of synapse - (NK + target), 
(n=25-27 conjugates/group, 4 experiments, distribution analyzed by Kolmogorov-Smirnov test). F) Quantification of 
MTOC-synapse distance in micrometers, not significant by Welch’s t test for means or Kolmogorov-Smirnov test 
(n=58-60 conjugates/group, 5 experiments). For (E-F), the gray box displays median, 25th, and 75th percentiles. ns=not 





MTOC polarization was not impaired. Thus, these data demonstrate that inhibition of glucose 
metabolism interfered with NK cell priming, leading to decreased levels of Gzmb protein 
production and altered actin accumulation at the IS. 
2DG-treated, MCMV-infected mice have impaired target clearance day 2 post-infection  
To examine the effects of glycolytic inhibition on NK cell function in vivo, we treated 
MCMV-infected mice with 2DG. Female WT mice were infected intraperitoneally with 1 x 105 
PFU of MCMV (~40% LD50) (41) and injected daily with either 19mg (1g/kg) of 2DG or vehicle 
(PBS). To determine whether 2DG administration altered NK cell cytotoxicity, in vivo target 
clearance was assessed. Syngeneic WT splenocytes (non-targets) and transgenic splenocytes 
expressing the MCMV-encoded activating ligand m157, which is only recognized by Ly49H+ NK 
cells, were differentially labeled and adoptively transferred into infected mice 2 days after 
infection (42). Clearance of targets in 2DG-treated MCMV-infected mice was significantly lower 
than in PBS-treated MCMV-infected mice, and was similar to baseline clearance in mock-infected 
mice (Figure 2.3A). This finding suggests that 2DG treatment impaired NK cell activation with 
MCMV infection and subsequent killing of target cells. The defect in target clearance in 2DG-
treated mice was not due to differences in NK cell numbers, as there were no significant differences 
in the number or percentage of NK cells (Figure 2.3B), or in Ly49H expression on NK cells (not 
shown), in the spleens or livers at this early timepoint. To determine whether NK cells had a defect 
in cytotoxic capacity, intracellular Gzmb and degranulation, as measured by cell-surface 
expression of CD107a, were tested. NK cells rapidly upregulate Gzmb and other cytotoxic proteins 
after infection with MCMV, and levels of Gzmb at day 2 in NK cells from infected mice were 
significantly higher than in naïve mice. However, there were no differences between 2DG- and 





Figure 2.3. 2DG treatment in vivo causes decreased target clearance during MCMV infection. 2-deoxy-ᴅ-
glucose (2DG)- or PBS-treated mice were analyzed on day 2 after infection with murine cytomegalovirus (MCMV). 
A) Equal numbers of labeled non-target splenocytes and target m157-transgenic splenocytes were injected i.v. and 
target clearance in the spleen was measured 4 hours later (n=7-12 individuals/group, 2 separate experiments). B) The 
number and percentage of NK cells isolated from the spleen or liver (n=7-8/group, 2 experiments). C) Flow plots and 
mean fluorescence intensity of granzyme B measured by flow cytometry in Ly49H+ (solid) and Ly49H- (hatched) NK 
cells from the spleen or liver (n=4/group, representative of 2 experiments). D) CD107a expression on splenocytes 
(n=7-8/group, 2 experiments). All statistical analyses are 1-way ANOVA with Tukey’s multiple comparison test, 




measured by mean fluorescence intensity (MFI) (Figure 2.3C). NK degranulation measured by 
cell-surface level of CD107a stained directly ex vivo was equivalent between 2DG-treated and 
PBS control mice (Figure 2.3D). Similarly, no differences in T cell numbers, Gzmb expression, or 
degranulation were detected (Supplementary Figure 2.2A-C). These results suggest that NK cells 
from 2DG-treated mice retained cytotoxic machinery, but were unable to mount productive target 
cell killing. 
2DG-treated mice produce normal levels of IFN-g during MCMV infection 
NK cell production of IFN-γ peaks at 1.5 days post-MCMV infection in response to 
systemic release of inflammatory cytokines, including IL-12 made by dendritic cells (43). While 
others have observed that IFN-γ production by LAK cells in vitro or by poly(I:C)-stimulated NK 
cells in vivo is susceptible to inhibition by 2DG (12), we previously demonstrated in vitro that 
naïve NK cell production of cytokine-driven IFN-γ is not inhibited by 2DG or by culture in 
glucose-free media (10). In agreement with our previous in vitro studies, there was no difference 
in IFN-γ production during MCMV infection with 2DG treatment (Supplementary Figure 2.3). 
These data also suggest an intact innate immune cytokine response to MCMV in the context of 
systemic 2DG injection, since early NK cell IFN-γ production is dependent on cytokines produced 
by antigen-presenting cells. 
2DG treatment causes susceptibility to MCMV infection. 
To test whether impaired NK cell clearance of targets correlates with susceptibility to 
infection, MCMV copy number was assessed in the spleen and liver. 2DG treatment was 
associated with higher viral burdens as early as day 2 post-infection in the spleen (Figure 2.4A), 
and by day 4 there was significant loss of viral control, evidenced by high viral copy number in 




one hypothesis is that NK cell IFN-γ is more important for control of MCMV in the liver, while 
NK cell cytotoxicity and Ly49H are responsible for control of infection in the spleen (44-47), 
which is consistent with our findings.  
By day 4 post-infection, 2DG treatment and high viral burden led to a decrease in the total 
number of splenocytes and liver lymphocytes (Figure 2.4C), with correspondingly decreased 
numbers of NK cells. There were no differences in the numbers of lymphocytes or NK cells with 
2DG treatment alone, and cell loss was specifically associated with uncontrolled MCMV infection 
in 2DG-treated mice. Low NK cell numbers at this timepoint were not due to decreased NK cell 
proliferation, since the percentage of NK cells with BrdU incorporation at day 4 post-infection was 
similar with and without 2DG treatment (Figure 2.4D). T cell numbers and BrdU incorporation 
were also similar with 2DG treatment (Supplementary Figure 2.2D, E). Thus, 2DG did not affect 
in vivo receptor-mediated proliferation of Ly49H+ NK cells, but did inhibit in vitro IL-15-
stimulated proliferation.  
Loss of viral control with 2DG treatment was associated with significant mortality, with 
80% of normally-resistant female B6 mice dying between days 5 and 6 post-infection (Figure 
2.4E). 2DG treatment alone without infection had no effect on survival. Mortality was dependent 
on both the dosage of virus and drug, as lower doses of MCMV or 2DG did not lead to mortality 
(Supplementary Figure 2.4). Together, these data show that glucose metabolism was crucial in the 
clearance of NK-dependent viral infection. 
IL-15 can rescue MCMV-infected, 2DG-treated mice 
In vitro, culture with IL-15 enhances NK cell metabolism, preferentially glycolysis, and 





Figure 2.4. 2DG treatment in vivo confers MCMV susceptibility. Female WT C57BL/6 mice were infected with 
1 x 105 PFU murine cytomegalovirus (MCMV) and treated daily with 2-deoxy-ᴅ-glucose (2DG). Viral copy number 
by quantitative PCR from the spleen and liver measured on (A) day 2 or (B) day 4 post-infection and is shown as 
copies of MCMV ie1 gene / copies of β-actin, x 1000 (n=3-8 individuals/group, 2 experiments, 1-way ANOVA on 
log-transformed data). C) Total numbers of lymphocytes and NK cells from the spleen or liver at day 4 post-infection. 
D) Representative flow cytometry and summary data showing the percentage of BrdU+ Ly49H+ NK cells (open) and 
Ly49H- NK cells (hatched), assessed 3 hours after BrdU injection. For (C) and (D), n=7-8/group, 2 experiments, 1-
way ANOVA with Tukey’s multiple comparison test. E) Survival of uninfected mice compared to infected mice 





glucose-free media was partially restored if NK cells were primed with IL-15 (10). Since we found 
that NK cell cytotoxicity was susceptible to glycolytic inhibition, we tested whether IL-15 could 
mitigate NK cell dependence on glucose. Thus, we tested whether IL-15 treatment could protect 
2DG-treated mice from MCMV infection. Mice were treated with the human IL-15 superagonist 
complex ALT-803, which is composed of IL-15 with the N72D mutation and IL-15Ra fused to 
the Fc of IgG1. ALT-803 has been shown to activate NK cells and CD8+ T cells, and exhibited 
anti-tumor and anti-retroviral activities in various experimental animal models (48-57). Mice were 
treated with 5µg of ALT-803 at 3 and 1 days prior to infection, which increases the number and 
percentage of NK cells in the spleen by 2- to 10-fold on the day of infection (not shown). ALT-
803 treatment significantly increased the baseline and maximal glycolytic and oxidative capacity 
of NK cells, but did not alter the ratio of oxidative phosphorylation to glycolysis (OCR/ECAR), 
suggesting that ALT-803-activated NK cells had high metabolic potential and activity but did not 
especially favor glycolysis (Figure 2.5A). This is in contrast to IL-15 treatment in vitro, which we 
previously demonstrated decreased the OCR/ECAR ratio (10). 
Treatment with ALT-803 rescued the deficit in NK cell target clearance at day 2 post-
infection in MCMV-infected, 2DG-treated mice (Figure 2.5B). ALT-803 treatment increased the 
total number of splenic NK cells and Gzmb expression, but neither of these was affected by 2DG  
(Figure 2.5C, D). There was no difference in splenic MCMV copy number at day 2 post-infection 
between 2DG-treated and PBS control mice that had been pretreated with ALT-803 (Figure 2.5E), 
suggesting enhanced viral control as compared to 2DG treatment alone (Figure 2.4A). However, 
liver MCMV copy number was increased with 2DG and ALT-803 treatment as compared to ALT-





Figure 2.5. NK activation with ALT-803 rescues MCMV susceptibility caused by 2DG treatment. A) Female 
wildtype C57BL/6 mice were treated with 5 μg ALT-803 twice, NK cells were purified from their spleens, and a 
glycolytic stress test was performed. Representative graph showing baseline, normal (+glucose), and maximal 
(+oligomycin) extracellular acidification rate (ECAR) in control vs. ALT-803-treated mice. Average ECAR, oxygen 
consumption rate (OCR), and OCR/ECAR ratio are shown after glucose addition (n=3 individuals/group, 2 separate 
experiments). B-E) ALT-803 treated mice were infected with 1 x 105 PFU murine cytomegalovirus (MCMV) and 
treated with 2-deoxy-ᴅ-glucose (2DG) daily. B) Clearance of m157-transgenic targets from the spleens of infected 
and uninfected mice +/- ALT-803 and 2DG on day 2 post-infection (n=5/group, representative of 2 experiments, 1-
way ANOVA). C) The number and percentage of NK cells isolated from the spleens or livers of mice in (B). D) Mean 
fluorescence intensity of granzyme B in all NK cells from (B). E) Viral copy number measured by quantitative PCR 
from the spleens and livers collected in b), shown as copies of MCMV ie1 gene / copies of  β-actin, x 1000. For (C-
E), n=10/group, 2 experiments, 1-way ANOVA, using log-transformed data for (E). F) Mice were given an additional 
dose of ALT-803 2 days after infection and followed for 10 days. Survival of mice with no treatment (gray dashed), 
2DG treatment (black), ALT-803 treatment (blue), or ALT-803 with 2DG (green) (n=10/group, 2 experiments, Log-




MCMV copy number in the liver of ALT-803-treated mice when compared to those with MCMV 
infection alone (Figure 2.4A), and loss of this protective effect with 2DG treatment. To assess 
survival, mice were monitored and received an additional dose of ALT-803 at day 2 post-infection. 
Mice receiving ALT-803 were completely protected from MCMV infection with 2DG treatment 
(Figure 2.5F). Thus, treatment with ALT-803 rescued both the target clearance and survival 
deficits induced by 2DG. 
IL-15 rescue is dependent on NK cells 
To determine whether enhanced target clearance and survival with ALT-803 were NK-
dependent, NK cells or CD8+ T cells, the two major cell types responsive to IL-15, were antibody-
depleted (a-NK1.1 or a-CD8b). Mice depleted of NK or CD8+ cells, or control-treated animals, 
received ALT-803 prior to MCMV infection with 2DG treatment (Figure 2.6A, Supplementary 
Figure 2.5A). NK depletion completely abrogated m157-transgenic target cell clearance and 
significantly increased MCMV copy number at day 2 post-infection (Figure 2.6B, C). Target cell 
clearance and MCMV copy number were not affected by CD8 depletion (Supplementary Figure 
2.5B, C), suggesting that bystander activation of CD8+ memory T cells by ALT-803 did not affect 
control of acute MCMV infection in naïve mice. NK-depleted mice had significantly increased 
mortality (Figure 2.6D), while CD8+ T cell depletion had no effect on survival (Supplementary 
Figure 2.5D), demonstrating that the survival of ALT-803–treated mice is dependent on NK cells. 
NK depletion did not result in the 80-100% lethality of 2DG treatment alone, indicating that ALT-
803 may have some antiviral effects on NK1.1- cells, e.g. intra-epithelial lymphocytes in the gut 
that can respond to IL-15, or DCs that produce and display IL-15 (58). It is also possible that NK 
cells remained or developed after antibody depletion treatment due to IL-15’s strong survival and 




majority of mice (data not shown), the efficacy of depletion in other organs was not evaluated. 
 
Figure 2.6. ALT-803 rescue of 2DG-treated mice requires NK cells, and ALT-803 priming can eliminate 
susceptibility to MCMV caused by mTOR inhibition. A) Mice were depleted of NK cells using α-NK1.1 at day -6 
and day 0, or treated with IgG2a, given two doses of ALT-803, and infected with 1 x 105 PFU murine cytomegalovirus 
(MCMV). 2-deoxy-ᴅ-glucose (2DG) was given every 24 hours, and mice were euthanized on day 2 for assessment of 
(B) clearance of m157-transgenic targets from the spleen and (C) viral copy number from the spleen and liver 
measured by quantitative PCR and log-transformed (n=10 individuals/group, 2 separate experiments, t test). D) To 
assess susceptibility, an additional NK depletion was given at day +3 (red, n=30); control mice were treated with 
IgG2a (black, n=23). Mice were followed for 10 days (3 separate experiments, log-rank Mantel-Cox test). E) Mice 
were infected with 1 x 105 PFU MCMV, given daily i.p. injections of 1.5mg/kg rapamycin (green) or vehicle (black), 
and monitored for susceptibility (n=10/group, 1 experiment). F) ALT-803 was given to MCMV-infected, rapamycin-
treated mice on the same schedule as for 2DG-treated mice, with doses at -3, -1, and +2 days relative to infection 
(n=10/group, 1 experiment). ns = not significant (p≥0.05), **=p<0.01, ***=p<0.001. 
mTOR inhibition leads to a similar survival defect with MCMV infection, which is rescued with 
IL-15 priming 
High-dose IL-15 signaling has been shown to lead to mTOR signaling, and mTOR activity 




led to susceptibility to MCMV infection similar to 2DG treatment. Based on our finding that 
glycolytic inhibition impaired NK cell responses and led to mortality with MCMV, we 
hypothesized that mTOR signaling is required for NK cell protective effects during MCMV, as 
was suggested by a prior study demonstrating increased viral copy number in rapamycin-treated 
MCMV-infected mice (59). Indeed, daily injection with 1.5 mg/kg rapamycin, an inhibitor of 
mTOR complex 1 (mTORC1), during MCMV infection led to susceptibility similar to 2DG 
treatment, with death 5-6 days post-infection (Figure 2.6E). Also similar to 2DG, IL-15 priming 
with ALT-803 was protective and completely abrogated the effects of rapamycin during MCMV 
infection (Figure 2.6F). This suggests that while IL-15 signaling has been described to upregulate 
mTOR and glycolysis, continued signaling through mTOR or maintenance of glycolysis is not 
required after IL-15-priming to sustain NK cell effector function.  
Human NK cell cytotoxicity is also reduced by treatment with 2DG. 
Relatively little is known about the effects of metabolism on human NK cell function, 
particularly cytotoxicity. To investigate whether human NK cells have a glycolytic requirement 
for cytotoxicity similar to the murine system, human NK cells were activated overnight with IL-
15 in the presence of varying doses of 2DG, then used in killing assays with K562 targets. Human 
NK cells were more resistant to 2DG than murine NK cells, but killing of K562 target cells was 
significantly decreased when cells were primed with IL-15 in the presence of 20-40mM 2DG 
(Figure 2.7A). Actin accumulation and MTOC polarization were measured and there were no 
significant defects in either (Figure 2.7B, C). Thus, both human and murine NK cell killing can be 
dampened by inhibition of glucose metabolism, though it is unclear if there are similar mechanisms 





Figure 2.7. 2DG decreases human NK cell cytotoxicity. Human NK cells were isolated from healthy donors, 
enriched using RosetteSep, and cryopreserved. Cells were later thawed and activated in 100ng/mL human IL-15 
overnight in various concentrations of 2DG. A) NK cells were washed and co-cultured with K562 targets for 4 hours 
at various E:T ratios. 2 representative killing assays are shown (n=technical duplicate, representative of 6 donors 
across 4 experiments). B-C) NK cells from control and 20-40mM 2DG were cultured at a 2:1 ratio with K562 cells, 
and imaged after 40 minutes.  B) Quantification of actin accumulation by area * intensity of synapse - (NK + target), 
(n=41-43 conjugates/group, 1 experiment). C) Quantification of MTOC-synapse distance in micrometers (n=67-
61conjugates/group, 2 experiments). Gray boxes show median, 25th, and 75th percentiles. Neither (B) nor (C) was 
significant by t test or Kolmogorov-Smirnov test (ns, p≥0.05). 
Treatment of CMV reactivation in a patient with an IL-15 superagonist 
Our results demonstrating that IL-15 treatment leads to enhanced protection against 
MCMV suggest that this cytokine may have therapeutic potential in patients. A 23-year-old CMV-
seropositive male with dyskeratosis congenita and aplastic anemia received a matched sibling 
allogeneic hematopoietic cell transplant (HCT) from his CMV-seronegative brother with full 
engraftment by 9 months (see Methods for case presentation). This patient experienced five 
episodes of CMV reactivation post-transplant, which manifested as viremia without organ disease 
(Figure 2.8A). Three episodes of CMV viremia within the 9 months post-HCT improved with 
antiviral therapy. A fourth episode at 18 months post-HCT resolved with CMVpp65-specific T 




At 51 months post-HCT, the patient again experienced CMV reactivation. Because of 
recurrent CMV viremia, this patient was treated with compassionate-use ALT-803. Absolute 
numbers of peripheral blood NK cells were within normal limits at the time of ALT-803 
administration. The patient received 4 weekly doses followed by 2 biweekly doses of ALT-803 at 
6 µg/kg per dose. No other anti-viral therapy was given before or during the time of ALT-803 
administration. Within 2 months, CMV viremia was below the limit of detection (Figure 2.8B), 
and CMV levels remained low for 7 weeks after ALT-803 therapy without additional antiviral 
therapy. Unfortunately, this patient experienced a recurrence of viremia when immunosuppressive 
therapy was required for treatment of post-transplant lymphoproliferative disorder. 
NK cell function in this patient before treatment and 7 or 14 days after each dose of ALT-803 was 
evaluated. The patient had an elevated proportion of CD57+NKG2C+ NK cells before treatment 
(~50%), consistent with the presence of CMV-adapted NK cells typically seen after CMV 
infection. This population of CMV-adapted NK cells was not altered by treatment with ALT-803 
(data not shown). NK cell IFN-γ production after overnight stimulation of cryopreserved 
peripheral blood mononuclear cells (PBMC) with IL-12 + IL-18 increased following ALT-803 
treatment (Figure 2.8C). Although the absolute IFN-γ response was lower in the patient’s cells 
than in PBMC from healthy controls treated with IL-12 + IL-18 (mean ± standard deviation: 44.69 
± 2.96% IFN-γ-producing NK cells, n=8 controls), the increased responsiveness in this patient 





Figure 2.8. ALT-803 treatment of CMV reactivation in a post-hematopoietic cell transplant patient. A) The 
patient’s course of cytomegalovirus (CMV) reactivation post-hematopoietic cell transplant (HCT), with periods of 
viremia detectable by quantitative PCR assay shown as orange bars. Post-transplant immunosuppression is shown as 
a blue bar. Years 1-4 post-HCT marked. B) During reactivation event #5, CMV levels responded to treatment with 
ALT-803 as indicated by arrows. Points below limit of detection (dashed line) at 137 copies/mL are rounded up. C) 
To assess IFN-γ production by the patient NK cells, PBMC were collected and cryopreserved before ALT-803 
treatment or 7-14 days after the listed ALT-803 dose. PBMC were thawed and stimulated with 10ng/mL IL-12 and 
100ng/mL IL-18 for 16 hours, then washed and plated for an additional 5 hours (n=4 technical replicates, statistical 
significance in a 1-way ANOVA compared to pre dose 1 shown above relevant column). *=p<0.05, ***=p<0.001. 
2.4 Discussion 
Here we examine the role of glycolysis in NK cell functions in vitro and in vivo. We found 
that the glucose metabolism inhibitor 2DG prevented IL-15-induced NK cell proliferation and 
priming of cytotoxicity in vitro. Using MCMV as an NK-dependent infection model, we 
demonstrate that administration of 2DG in vivo impaired NK-mediated target clearance and 
significantly increased susceptibility of mice to infection. These defects could be rescued in an 
NK-dependent manner with the IL-15 superagonist ALT-803. Treatment with an mTORC1 
inhibitor led to a similar susceptibility to infection, which was also rescued by ALT-803 priming, 
suggested that IL-15-primed NK cells have mTOR-independent sustained effector function. In a 
patient, treatment with ALT-803 also boosted NK cell function and was associated with clearance 




Our in vitro findings show that culture in 2DG blocks the ability of IL-15 to activate NK 
cell functions including proliferation, Gzmb production, and acquisition of enhanced cytotoxic 
functions. Cytotoxic defects were target cell-line specific, suggesting that that certain pathways of 
NK cell activation may be able to overcome the dampened activation state of 2DG-treated NK 
cells, or that certain pathways require glycolytic metabolites for signaling. Possible mechanisms 
for 2DG’s effects on cytotoxicity include downregulation of Gzmb, leading to less cytotoxic 
granules, and altered actin accumulation at the immunological synapse. Actin accumulation is 
crucial for NK cell cytotoxicity, as evidenced by diseases associated with defects in actin 
accumulation such as Wiskott-Aldrich Syndrome, where NK cells fail to form conjugates or kill 
target cells (61). Although conjugation to target cells and MTOC polarization towards the synapse 
appeared normal in 2DG-treated NK cells, altered actin accumulation could be indicative of a less 
stable conjugation that could lead to slower or less effective killing, or could interfere with release 
of target cells and thus interfere with serial killing by NK cells. Interestingly, Wiskott-Aldrich NK 
cell defects can be reversed by IL-2 administration, as IL-2 activates an alternate actin 
polymerizing pathway (62, 63). Since IL-15 and IL-2 are closely related, this may provide a 
potential mechanism for IL-15 rescue of 2DG-induced deficits. 
The observed target clearance defect caused by 2DG treatment resulted in higher viral 
replication, overwhelming infection, and mortality. MCMV infection has a steep LD50 curve (41), 
and loss of control of infection with 2DG treatment phenocopies mortality observed in mice 
depleted of Ly49H+ NK cells or total NK cells (24). Notably, not all NK cell functions were 
affected by 2DG, with intact IFN-g production in vitro (10) and in vivo, and proliferation in vivo. 
Normal proliferation was somewhat surprising, as proliferating lymphocytes have been well-




infected mice, such as the presence of additional cytokines or activating receptor ligands, that 
could allow NK cells to proliferate despite glycolytic inhibition. The underlying mechanism for 
this glycolytic requirement for NK cell cytotoxicity can be partially explained by some of the 
findings here. 2DG decreases Gzmb upregulation in response to IL-2 + IL-12 (12) or IL-15 
stimulation in vitro, and after poly(I:C) injection in vivo (12). While 2DG did not appear to inhibit 
Gzmb upregulation in response to MCMV infection, this could be explained by different kinetics 
of Gzmb accumulation in response to different in vivo stimuli, or accumulation of Gzmb in 2DG-
treated NK cells that are not actively degranulating and killing target cells. It is possible that killing 
defects in vivo are caused by changes in actin dynamics rather than Gzmb. Although actin 
accumulation defects did not alter conjugation in vitro, this may be due to the ready abundance 
and proximity of target cells. In vivo actin dynamics are crucial in NK cell trafficking and minor 
defects in the ability to polymerize actin could lead to decreased numbers of NK cells at sites of 
infection.  
Although 2DG administration is confounded by systemic effects, prior model systems have 
demonstrated that 2DG does not lead to generalized susceptibility to infection, as 2DG treatment 
did not increase susceptibility to Listeria infection (66) and decreased virulence of other viruses, 
including HSV (67-69). Combined with our evidence that Ly49H-specific target clearance is 
decreased with 2DG and that deficient target clearance and survival can be rescued through IL-15, 
there is clear evidence of NK-specific defects with 2DG. However, NK cell-specific genetic 
knockouts of metabolic enzymes are necessary to interrogate the role of metabolism in NK cell 
functions in vivo. 
While NK cells require glycolysis during viral infection for optimal killing, pre-treatment 




previously observed in vitro for IFN-γ (10). ALT-803 injection altered the metabolic rate of NK 
cells leading to increased glycolysis and oxidative phosphorylation, and preserved NK cell-
mediated target clearance in the presence of 2DG. Mice pre-treated with ALT-803 were protected 
from MCMV infection when treated with either a glycolytic inhibitor or an inhibitor of mTORC1, 
suggesting that these pathways are not critical for IL-15-primed NK cell antiviral responses.  
The underlying mechanism for IL-15 reversing NK cell dependence on glucose metabolism 
and mTOR activation is unknown. IL-15 is well described to promote NK cell differentiation, 
expansion, Gzmb expression, cytokine production, and cytotoxicity (32, 70). We have previously 
shown that IL-15 upregulates NK cell metabolic capacity in vitro, especially glycolysis (10), and 
here we demonstrate that ALT-803 significantly increases metabolism in vivo, suggesting that IL-
15 fundamentally alters cellular metabolic requirements. This altered metabolic state could lead to 
more flexible fuel usage by NK cells, allowing alternate fuels such as fatty acids, glutamine, or 
pyruvate to fuel NK cell function if glucose metabolism is limited. Alternately, we now have 
evidence that both cytokine-activated IFN-γ production (10) and clearance of target cells during 
MCMV infection become less metabolically-dependent with IL-15 pre-treatment, suggesting that 
IL-15 increases the range of stimuli and functions that are metabolically-independent. Recent 
studies have demonstrated a role for mTORC1 in IL-15 priming and NK cell responses to MCMV. 
mTORC1 activates glycolysis through HIF-1a, c-myc, and AKT signaling, in addition to 
orchestrating broader cell growth programs (71). High-dose IL-15 signaling has been shown to be 
dependent on mTORC1 (11, 59), which likely contributes to IL-15-induced upregulation of 
glycolysis. However, here we demonstrate for the first time that after IL-15 priming, mTORC1 
signaling is not required for in vivo NK cell function, as shown by complete protection against an 




findings distinguish the effects of mTORC1 signaling on priming versus maintenance of NK cell 
effector function.  
The concept of augmenting the antiviral effects of NK cells with IL-15 agonists may be 
particularly relevant in patients post-HCT and/or patients receiving immunosuppression targeting 
T cell responses. Following HCT, NK cells are the first lymphocyte population to emerge from 
the new bone marrow and thus represent an important population to target for anti-leukemic and 
infection responses (72). In some cases, NK cells are reconstituted after HCT but are less 
functional for months, with reduced capacity for IFN-γ production and cytotoxicity (73, 74). Here, 
we show that treatment with an IL-15 superagonist significantly boosted NK cell antiviral 
responses in mice, and in one patient was associated with clearance of CMV infection in the 
absence of other antiviral therapy. Although limited conclusions can be drawn from a single 
patient, these studies suggest that clinical investigation of IL-15 agonists for treatment of refractory 
viral infections, particularly CMV, is warranted. Here, we demonstrate that IL-15 activation of NK 
cells decreases NK cell reliance on glucose metabolism and mTOR signaling in vivo, and may be 
a strategy to enhance NK cell function in metabolically challenging environments such as 
inflammatory and tumor microenvironments in patients.  
In summary, our findings suggest that limiting glucose metabolism impairs NK cell killing 
and host antiviral responses to CMV, which can be rescued with IL-15-based priming. Such 
therapies may be particularly beneficial for patients after HCT, who may have normal numbers of 
NK cells but poor NK cell function. Additional investigations of the mechanisms by which 
metabolism alters NK function will be important for targeting these innate immune lymphocytes 
for immunotherapy, and may provide insight into the metabolic regulation of killing in other 




2.5 Materials and Methods 
Mice and MCMV infection 
All mice were maintained in specific pathogen-free conditions, used between 6-12 weeks 
of age, and euthanized in accordance with institutional guidelines. C57BL/6 mice were purchased 
from Charles River Laboratories or from Jackson, and m157-transgenic mice on the C57BL/6 
background (42) were bred in-house. 7-11 week old C57BL/6 female mice were injected i.p. with 
1 x 105 PFU of Smith strain salivary gland MCMV (ATCC, prepared in BALB/c mice), or media 
as a control. 19mg of 2DG was given i.p. after infection and every 24 hours (~1g/kg per mouse), 
or PBS as a control. For proliferation assays, mice were injected with 2mg BrdU (BD Biosciences) 
i.p. 3 hours before harvest. For IL-15 superagonist treatment, 5µg ALT-803 (Altor BioScience) 
was injected i.p. 3 days and 1 day before MCMV infection, and 2 days after infection. For NK and 
CD8 depletion, 100µg of a-NK1.1 (PK136, BioXcell), 250µg a-CD8b (53-5.8, BioXcell), or 
100µg murine IgG2a (C1.18.4, BioXcell) was administered i.p. 6 days before MCMV infection, 
the day of infection, and 3 days after infection. Mice were bled 24h before infection or spleens 
were examined at time of euthanasia to confirm NK or CD8+ T cell depletion by loss of CD3-
NKp46+DX5+ or CD3+CD8a+ cells (not shown). Rapamycin was solubilized in 4% EtOH, 5% 
Tween 80, 5% PEG400, and water, and 30µg (~1.5mg/kg) or an equivalent amount of vehicle was 
injected i.p. daily during MCMV infection.  
In vitro assays 
Primary splenocytes from female C57BL/6 mice were cultured in RPMI 1640 (Mediatech) 
supplemented with 10% FBS (Sigma-Aldrich), L-glutamine to a final concentration of 4mM 
(Sigma), 50µM 2-ME (Sigma), and antibiotics (penicillin/streptomycin). NK cells were enriched 




Technologies). Purity ranged from 55-90% at time of plating, and 77-99% after 72h activation. 
For IL-15 activation, purified NK cells were cultured in 100ng/mL IL-15 (PeproTech) for 72 hours 
with or without 1mM 2DG. For proliferation assays, purified NK cells were stained with 1µM 
CFSE before culture.  
For mouse NK cell killing assays, NK cells were washed and plated in V-bottom plates at 
estimated 10:1, 5:1, and 1:1 NK:target ratios with 1 x 104 CellTrace-labeled target cells, including 
RMA-S (from W. Yokoyama), Ba/F3-m157 (from W. Yokoyama (29)), and YAC-1 (from ATCC). 
Cell lines tested negative for mycoplasma. Effector:target ratios were calculated based on NK cell 
purity by flow cytometry. After 4 hours, cells were stained with 7-AAD for 15-30 minutes before 
flow cytometry, and specific lysis was calculated by subtracting the percentage of 7-AAD+ target 
cells from wells without effectors. For mouse NK cell conjugation assays, NK cells were labeled 
with CFSE and Ba/F3-m157 target cells with CellTrace Violet (CTV). Cells were spun down at a 
1:1 NK:target ratio, incubated in 37C for 15, 30, or 120min, and then vortexed gently and fixed in 
1% paraformaldehyde. Percent conjugated NK cells was calculated by calculating the percentage 
of CFSE+CTV+ cells compared to all CFSE+ cells.  
Human NK cells from healthy donors were enriched using RosetteSep (StemCell), For 
killing assays, previously cryopreserved NK cells were plated in 100ng/mL IL-15 (Miltenyi) and 
varying concentrations of 2DG for 22-26 hours, followed by incubation with labeled K562 targets 
for 4 hours at the indicated E:T ratios. Cells were then stained with 7-AAD and specific lysis 
calculated. For conjugation assays, NK cells were incubated with IL-15 and 2DG for 22-26 hours, 
then co-cultured with K562 targets at a 2:1 ratio for 40-50 minutes. To assess patient NK cell 




IL-12 (10 ng/mL) and IL-18 (100 ng/mL), washed, plated in replicates of 4 per sample, and 
incubated for an additional 5 hours prior to intracellular staining for IFN-γ protein.  
Flow cytometry 
Cell viability was measured by live/dead stain (Zombie Yellow, BioLegend), followed by 
blocking with anti-FcγRIII (2.4G2) prior to surface staining. Cells were fixed with 1% 
paraformaldehyde for surface analysis, or fixed with Cytofix/Cytoperm (BD Bioscience) for 
intracellular staining. For intranuclear staining, cells were fixed in Cytofix/Cytoperm and 
Cytoperm Plus buffer (BD) and DNAse treated. Data was acquired on a Cytek-modified FACScan 
(BD and Cytek) or LSRFortessa (BD); data was analyzed using FlowJo 7.6.5. Geometric mean 
fluorescence intensity and % proliferated were calculated by FlowJo. The following fluorochrome-
conjugated antibodies were used: CD3ε (145-2C11, BD/BioLegend), CD4 (GK1.5, Leinco), CD8α 
(53-6.7, BD), CD11b (M1/70, BD), CD11c (HL3, BD), CD19 (eBio1D3, eBiosciences), IFN-γ 
(XMG1.2, BioLegend), Ly49H (3D10, BioLegend), NK1.1 (PK136, BD), NKp46 (29A1.4, BD), 
Gzmb (GB12, Invitrogen/Life Technologies), and BrdU (BrdU kit, BD). CD107a was stained by 
incubating splenocytes with a-CD107a (1D4B, BD) and GolgiStop (monensin, BD) for 4 hours at 
37˚C.  
Confocal microscopy 
Purified NK cells and Ba/F3-m157 or K562 targets were co-cultured at a 2:1 ratio, 
incubated for 20 minutes at 37C, applied to poly-L-lysine-coated coverslips, and incubated for an 
additional 20 minutes. Slides were fixed in Cytofix/Cytoperm (BD) + 0.1% Triton X-100 (Sigma), 
then stained with the following antibodies: Ly49H (3D10, BioLegend), Biotin-Tubulin (236-
10501, ThermoFischer), Perforin (dG9, BioLegend), Gzmb (GB11, BioLegend), Phalloidin 




were acquired on a Leica SP8 laser scanning confocal microscope equipped with a 100X 1.45 NA 
objective. Excitation was by tunable white light laser and emission was detected by HyD detector 
(Leica). Data were acquired using Leica LASAF and analyzed in Volocity 6.1.1 (Perkin Elmer) 
and 6.3 (Quorum Technologies). Measurement of MTOC-synapse distance was single-blinded. 
Actin accumulation measurements were unblinded, and consisted of the total area * average 
intensity of three 1µm squares spaced evenly or where there was sufficient actin staining. Actin 
accumulation was calculated by area * intensity of synapse – (NK + target) (75). 
Extracellular flux 
 Extracellular flux assays were performed using a XF96 Analyzer (Seahorse Bioscience). 
Purified splenic NK cells were cultured for 72 hours in 100ng/mL IL-15 with or without 1mM 
2DG, or NK cells were purified from ALT-803- or control-treated mice. Cells were then washed 
and plated in at least duplicate for extracellular flux analysis of oxygen consumption rate (OCR) 
and extracellular acidification rate (ECAR) as previously described (10, 76). Glycolysis stress tests 
were performed in glucose-free DMEM supplemented with L-glutamine, sodium pyruvate, and 
5% dialyzed FBS. Drug concentrations during the assay were as follows: glucose 10mM, 
oligomycin 100nM, 2DG 100mM. 
MCMV quantitative PCR 
 5mm3 tissue pieces were minced and placed in Gentra Puregene Cell Lysis Buffer 
(Qiagen), and DNA extracted following the manufacturer’s recommended protocol and diluted to 
20-50ng/ml. MCMV immediate-early gene 1 (ie1)-specific primers and probe were used to 
determine viral copy number as described (47), and normalized to b-actin (Actb). Reactions were 
run in duplicate in on a 7500 Fast Real-Time PCR instrument (Applied Biosystems) with an 




MCMV, and all values below 100 were rounded up. Graphs represent [(copies MCMV ie1)/(copies 
Actb)] x 1000. Statistics were performed on log-transformed data. 
In vivo target clearance assay 
Splenocytes were harvested from C57BL/6 mice and C57BL/6 m157-transgenic mice, 
stained with 10µM or 1µM CFSE, and mixed together in a ~1:1 ratio. 7-20 x 106 cells were injected 
by tail vein into mice that had been infected with MCMV two days prior and treated daily with 
2DG or PBS. Mice were treated with 2DG, but not ALT-803, prior to the clearance assay. The 
remaining labeled cells in the spleen were analyzed 4 hours after transfer. Percent target clearance 
was calculated by comparing the ratio of m157-transgenic splenocytes (m157tg, targets) to WT 
splenocytes (non-targets) recovered to that originally injected: 1 – (%m157tg/%WT cells at 4 
hr)/(%m157tg/%WT cells input) x 100. 
Patient case presentation  
A 23-year-old CMV-seropositive male with dyskeratosis congenita and severe aplastic 
anemia received a matched sibling allogeneic hematopoietic cell transplant (HCT) from his CMV-
seronegative brother. Conditioning was reduced intensity (fludarabine 40 mg/m2/day x 4, 
cyclophosphamide 50 mg/kg x1, total body irradiation 2 Gy, and alemtuzumab 0.2 mg/kg/d x 5). 
Graft source was peripheral blood (9.3 x 106 CD34+ cells/kg), and the donor was his healthy 
brother (CMV seronegative). Graft-versus-host disease (GVHD) prophylaxis was with 
cyclosporine and mycophenolate mofetil and viral prophylaxis with high-dose acyclovir (800 mg 
5 times daily) for ~25 days. Engraftment was complete as documented on day +28, and 
immunosuppressive medications for GVHD prophylaxis were discontinued 9 months post-
transplant. The patient developed no acute or chronic GVHD, relapse, or any major bacterial or 




reactivation without organ disease. Within the first 100 days post-HCT, he had one CMV 
reactivation episode treated successfully with valganciclovir and the viremia resolved after 21 
days. The second episode occurred 4 months after HCT and resolved after 3 months of treatment 
with valganciclovir followed by foscarnet. The third episode occurred 9 months post-HCT and 
resolved after 6 months of treatment using maribavir (clinical trial NCT01611974) followed by 
valganciclovir. The fourth episode occurred 18 months post-HCT and resolved after 3 months with 
treatment using CMVpp65-specific T cell adoptive transfer (3 doses; NCT02136797 sponsored by 
Atara Biotherapeutics). This viral remission was durable and lasted for 31 months, at which time 
(51 months post-HCT) the patient experienced another episode of reactivation. Mutation testing 
for antiviral resistance was negative.   
Statistics 
Statistics calculated in Prism 7 include mean, SEM, median, 25th/75th percentiles, student’s 
t-test, Log-rank Mantel-Cox test, ordinary one-way or two-way ANOVA. All treatment groups 
used in an experiment were included in the ANOVA analysis, including controls; in non-survival 
experiments, mice that appeared uninfected were excluded from analysis. Tukey’s test and Sidak’s 
test were used to correct for multiple comparisons, and adjusted p values are shown. The 
Kolmogorov-Smirnov test was calculated in Statistical Analysis System (SAS Institute) v9.4. P 
values represent 2-tailed probability, a=0.05. Data are presented with data averaged from each 
mouse or experiment as a separate point, and/or as mean +/- SEM.  
Animal study approval 
All animal studies were performed at Washington University or Baylor College of 
Medicine using an Animal Studies Committee (ASC) approved protocol, and conducted in 




Human study approval 
Written informed consent was obtained from the patient presented here in agreement with 
the guidelines of the University of Minnesota Human Research Protection Program. FDA approval 
for compassionate use of ALT-803 was obtained (IND #132197).   
2.6 Supplementary Figures 
 
Supplementary Figure 2.1. Effects of 1mM 2DG culture on NK cell metabolism and killing. Purified NK cells 
were cultured in 100ng/mL IL-15 with 1mM 2-deoxy-ᴅ-glucose (2DG) for 72 hours. A) Percentage of cells alive by 
trypan blue staining and B) percentage of NK cells recovered after 72-hour culture out of total number of NK cells 
plated (n=11 individuals, 7 separate experiments, paired t test). C) Specific lysis of RMA-S and YAC-1 target cells 
after culture with IL-15-activated NK cells that had been cultured in normal media (black) or 1mM 2DG (green) (n=4 





Supplementary Figure 2.2. T cells upregulate Gzmb and proliferate, but are not affected by 2DG treatment. 
The mice from Figure 4 (C57BL/6 females infected with 1 x 105 PFU murine cytomegalovirus and treated with 1g/kg 
2-deoxy-ᴅ-glucose daily) were assessed for T cell function. A) The proportion of CD19+ B cells, CD3+CD4+ T cells, 
and CD3+CD8+ T cells in the spleen at day 2 post-infection (n=4/group, representative of 2 experiments). CD3+NK1.1- 
cells were assessed using flow cytometry for (B) degranulation without targets by CD107a staining and (C) Gzmb 
expression. D) Proportion of CD19+ B cells, CD3+CD4+ T cells, and CD3+CD8+ T cells in the spleen at day 4 post-
infection (n=3-4/group, representative of 2 experiments). C) BrdU incorporation 3 hours after injection (n=7-8 






Supplementary Figure 2.3. IFN-γ production by NK cells during MCMV infection is not inhibited by 2DG. 
Mice were infected with 1 x 105 PFU murine cytomegalovirus (MCMV) and injected with 1g/kg 2-deoxy-ᴅ-glucose 
(2DG) or PBS. Mice were sacked at 36 hours post-infection for flow cytometry (n=4-5 individuals/group, 2 separate 




Supplementary Figure 2.4. MCMV susceptibility is dependent on the dose of 2DG and the inoculum of MCMV. 
8-week-old female C57BL/6 mice were infected with murine cytomegalovirus (MCMV) and injected daily with 2-
deoxy-ᴅ-glucose (2DG). Either the MCMV inoculum or 2DG dosage was varied. Survival is shown for 10 days, with 
the same mice for 1 x 105 pfu MCMV + 1000mg/kg 2DG (black) shown in both graphs (n=5/group, 1 experiment, 





Supplementary Figure 2.5. The effects of ALT-803 are not mediated through CD8+ T cells. A) Mice were 
depleted of CD8+ T cells using α-CD8b, or were treated with IgG2a as a control. Mice were then given two doses of 
5µg ALT-803, infected with 1 x 105 PFU murine cytomegalovirus (MCMV), and injected with 1g/kg 2-deoxy-ᴅ-
glucose (2DG) daily. B) Clearance of m157-transgenic targets from the spleen and (C) copy number of MCMV in the 
spleen and liver were assessed on day 2 (n=9-10 individuals/group, 1 experiment, copy number data log-transformed, 
analysis by t test). D) Mice were given an additional dose of ALT-803 and either α-CD8b (green, n=10) or IgG2a 
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Chapter 3  
Cox10 is Required for Expansion of Ly49H+ 











Studies in diverse cell types have rediscovered the importance of basic cellular metabolism 
in regulating immune responses. For example, glycolytic and oxidative metabolism are counter-
regulated in T cells to develop inflammatory effectors vs. memory or regulatory cells, respectively. 
NK cells, which are first responders for viral infection and malignant transformation, may be 
similarly regulated. We recently showed that NK cell cytotoxic activity during infection with 
murine cytomegalovirus (MCMV) required glucose metabolism, whereas other NK cell responses 
such as cytokine production did not. We hypothesized that oxidative metabolism would be 
required for some of these glycolysis-independent responses. To test this, we examined responses 
to MCMV in mice with an NK-specific deletion of Cox10, which is required for assembly of 
electron transport chain complex IV. These “Ncr1-Cox10D/D” mice had normal NK cell 
development and numbers, without evidence of metabolic defects at baseline. However, Ncr1-
Cox10 D/D mice were more susceptible to MCMV infection, with impaired expansion of MCMV-
specific Ly49H+ NK cells and failure to generate “memory” NK cells. Similar defects in expansion 
were found when Cox10-deficient NK cells were proliferated in vitro with Ba/F3-m157 cells. 
Decreased Ly49H-driven proliferation in vitro was associated with decreased levels of 
mitochondrial reactive oxygen species, without a significant increase in the rate of apoptosis of 
Cox10-deficient NK cells. Thus, we find that Cox10 is required by NK cells to expand in response 
to Ly49H stimulation during MCMV infection. This is the first study directly examining the role 






Work in multiple immune cell types has found that metabolic pathways produce signals 
that regulate immunological function, and vice versa. As a general principle, two of the most 
important metabolic pathways in a cell—glycolysis and oxidative phosphorylation (OXPHOS)—
are counter-regulated to produce either inflammatory and proliferative functions, or memory and 
regulatory functions, respectively (1-4). However, oxidative metabolism is critical in many cellular 
functions outside of this generalization. OXPHOS uses fuel from various sources, including 
glycolysis, fatty acid b-oxidation, and the tricarboxylic acid cycle, to produce energy in the form 
of ATP for the cell. Additionally, OXPHOS is a major intracellular source of reactive oxygen 
species (ROS), which can assist in signal transduction or cause damage if uncontrolled (5-7). We 
are interested in understanding how natural killer (NK) cells, innate lymphocytes that are critical 
in the early response to viral infection and malignant transformation, are regulated by the balance 
of glycolytic and oxidative metabolism.  
Our previous work has found that murine NK cells primarily use glucose-driven OXPHOS 
at rest, similarly to other naïve immune cell types (1, 3). In vitro, both murine and human NK cell 
production of IFN-g can be inhibited by oligomycin, an ATP synthase inhibitor (8, 9); however, 
murine NK cells are only susceptible to oligomycin if stimulated through NK activating receptors 
and not by inflammatory cytokines, indicating that different stimuli may have different metabolic 
requirements (8). Compared to these findings in vitro, relatively little work has examined the role 
of oxidative metabolism in regulating NK cell function in vivo. Using a model of glycolytic 
inhibition by injection of 2-deoxy-D-glucose in vivo, we found that even though aerobic glycolysis 
is required for inflammatory activation and proliferation of other cell types (1, 2), 2DG treatment 




impairment led to decreased NK cell cytotoxicity (10). Based on these findings, we speculate that 
NK cell proliferation in response to viral infection might be dependent on oxidative metabolism 
rather than aerobic glycolysis. In order to test this hypothesis, we used an NK-specific model of 
genetic Cox10 deficiency. 
COX10 is a protoheme farnesyltransferase, a subunit required for assembly of cytochrome 
c oxidase (COX), otherwise known as Complex IV of the mitochondrial electron transport chain 
(ETC). COX accepts electrons from the other complexes and fixes them to O2, making it a rate-
limiting step of OXPHOS (11). Additionally, its interaction with cytochrome c gives it an 
important role in regulating apoptosis. Defects in Complex IV, including Cox10 deficiency, are 
known to cause mitochondrial disease in humans, manifested as progressive degradation of 
neurons, muscle, kidneys, and/or liver (11-13). Similar findings appear in tissue-specific mouse 
models of Cox10 deficiency (14-16). Cox10-deficient T cells had higher rates of apoptosis after 
activation than wildtype T cells, leading to increased susceptibility to infection (17). Thus, COX10 
appears to play a role in vivo in regulating immune cell function. We generated mice with NK-
specific Cox10 deficiency that allowed us to interrogate the role of oxidative metabolism in a cell-
specific manner in vivo.  
In order to examine NK cell antiviral function, we used the well-characterized murine 
cytomegalovirus (MCMV) infection model. In the first 48 hours, systemic inflammatory cytokines 
activate NK cells, leading to their priming and production of interferon gamma (IFN-g) (18, 19). 
NK cells bearing the Ly49H receptor (~50% in naïve mice) specifically respond to the presence 
of the MCMV-encoded protein m157 on infected cells, leading to enhanced killing of infected 
cells and preferential proliferation of the Ly49H+ population that peaks around day 7 post-infection 




functionality that can persist for months (22). Thus, MCMV infection provides a model to study 
multiple NK cell functions, including proliferation and NK cell “memory”.  
In this study, we characterized a mouse with an NK-specific defect in oxidative 
metabolism, specifically loss of a subunit of cytochrome c oxidase (COX10). Cox10-deficient NK 
cells developed normally and have normal energy production at baseline. However, Cox10 was 
required for optimal expansion of the Ly49H+ subset in response to MCMV infection. In modeling 
the proliferation response using m157-expressing cells in vitro, we found that Cox10-deficient NK 
cells did not have significantly higher rates of apoptosis, but did have decreased production of 
mitochondrial ROS. Deficient proliferation of Cox10-deficient NK cells during MCMV infection 
in vivo was linked to increased susceptibility at higher doses of MCMV and failure to generate 
“memory” NK cells. 
3.3 Results 
Cox10-deficient NK cells develop normally 
In order to study the effects of oxidative metabolism and mitochondrial health on NK cell function, 
we generated an NK-specific model of Cox10 deletion (Ncr1-Cox10D/D). Cre recombinase was 
driven by the Ncr1 (NKp46) gene in mice, combined with a loxp-stop-loxp yellow fluorescent 
protein (YFP) reporter for Cre activity, and a floxed Cox10 allele (14). Cox10-deficient NK cells 
appeared at normal proportions and numbers in the blood, bone marrow, liver, lungs, lymph nodes, 
and spleen (Fig. 3.1A, Supplementary Fig. 3.1A) of adult mice. Additionally, the proportion of 
NK cells that were YFP+ in Ncr1-Cox10D/D mice was normal, indicating that Cre induction (and 
therefore deletion of Cox10) did not lead to NK cell loss (Fig. 3.1B). We confirmed deletion of 





Figure 3.1. Cox10-deficient NK cells develop normally. Organs were collected from 8-12 week old mice of both 
sexes from Ncr1-Cox10D/D (orange square) and Ncr1-YFP reporter (WT, black circle) strains. Bone marrow (2 femur, 
2 tibia) n=7 individuals/group, 3 separate experiments. Liver n=7, 3 exp. Lung n=8-9, 3 exp. Lymph node (average of 
axillary & inguinal) n=8-9, 3 exp. Spleen, n=10-11, 3 exp. Blood n=10, 4 exp. A) # of NK cells was calculated by 
%NK1.1+CD3- cells x # of cells per organ. B) The Ncr1 gene (NKp46) drives Cre expression, turning on a YFP 
reporter. Representative flow and summary data showing the induction of YFP (n=13/group, 6 separate experiments). 
C) NK cells were enriched from spleens and sorted by YFP expression. mRNA was extracted from cells and expression 
of Cox10 was analyzed by quantitative real-time PCR. Fold change by DDCt normalized to YFP+ WT levels in two 
separate experiments. D) Representative flow cytometry show maturity staging by CD11b x CD27 staining, and 
summary data from YFP+ NK cells from various organs (n=5-6, 2 exp). E) Representative histograms show expression 
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NK cell development in Ncr1-Cox10D/D mice was normal despite loss of the Cox10 gene. 
Cox10-deficient NK cells showed normal maturity by CD11b and CD27 staining (Fig. 3.1D, 
Supplementary Fig. 3.1B) (23), indicating that Cox10 is not required for development of mature 
NK cells. In order to examine their reactivity, we assessed receptor expression on Cox10-deficient 
NK cells. Normal levels were detected of the NK activating receptors NKp46, NKG2D, 
NKG2C/E, Ly49D, and Ly49H, the inhibitory receptors Ly49C/I and NKG2A, and co-receptors 
DNAM-1 and CD49b (DX5) (Fig. 3.1E, Supplementary Fig. 3.1C). Expression of CD122, the IL-
2/IL-15 receptor beta chain, was also the same between Cox10-deficient and control NK cells (Fig. 
3.1E, S3.1C). Based on our panel, Cox10-deficient NK cells expressed NK receptors at the same 
level as wildtype NK cells, and were thus likely to recognize the same stimuli. 
Cox10-deficient NK cells have normal mitochondrial function at baseline 
 Next, we examined the mitochondrial health and energy production capacity of Cox10-
deficient NK cells at baseline. Transmission electron microscopy (TEM) showed that naïve Cox10-
deficient NK cells had similar numbers of mitochondria per cell in each slice, which appeared to 
have normal “orthodox” ultrastructure (24). The folds of cristae were visible in most mitochondria, 
with the majority of the organelle’s volume taken up by the matrix (Fig. 3.2A). We did not find 
any significant defects in oxygen consumption by Cox10-deficient NK cells in naïve cells. There 
were no changes in baseline or maximal oxygen consumption rate as measured by extracellular 
flux analysis (Fig. 3.2B), although this analysis was done on bulk NK cells without selection for 
Cre induction using the YFP reporter. These findings indicate that Cox10 deficiency does not 
detectably affect mitochondrial metabolism of naïve NK cells. 
We also tested energy production and IFN-g production in Cox10-deficient NK cells 




using the ATP synthetase inhibitor oligomycin prevents NK cell activation and IFN-g production 
(8). Unlike NK cells treatmed with oligomycin, Cox10-deficient NK cells produced normal levels 
of IFN-g with short-term stimulation through both activating receptors (NK1.1, Ly49H) and 
inflammatory cytokines (IL-12 + IL-18, IL-12 + IL-15) (Fig. 3.2C). This was associated with 
normal ATP production at baseline (IgG control) and after stimulation, although these 
measurements included ~30% YFP- (Cre-) NK cells (Fig. 3.2D). As resting NK cells primarily 
produce ATP through oxidative phosphorylation (8), this indicates that oxidative metabolism is 
intact enough for normal energy production in Cox10-deficient NK cells, and normal activation 
and IFN-g production after activation with either receptor and cytokine stimuli.  
 
Figure 3.2. Cox10-deficient NK cells have normal function and energy production at baseline. A) NK cells were 
enriched and sorted from Ncr1-Cox10D/D and WT mice, then prepared for TEM. Representative images show similar 
mitochondrial morphology. B) Purified NK cells were analyzed by extracellular flux assay; technical duplicates 
(mean±SEM) from one of three mitochondrial stress test assays. Baseline oxygen consumption rate (OCR) in NK cells 
is similar to maximal OCR (after oligomycin & FCCP); black circle = wildtype, orange square = Cox10-deficient. C) 
Splenocytes were stimulated for 6 hours with various stimuli, and IFN-g was measured by intracellular flow cytometry. 
N=4-6 individuals/group, 3 separate experiments, except Ly49H (n=2-4, single exp). D) Purified NK cells were plated 
with various stimuli for 6h, before harvest for a luminescence-based ATP assay. Readings were corrected by the cell 
count (technical duplicates, 2 experiments plus single replicate from a third experiment.) Ns=not significant (p≥0.05) 




Cox10-deficient Ly49H+ NK cells expand less during MCMV infection in vivo 
To examine the function of Cox10-deficient NK cells in vivo, Ncr1-Cox10D/D mice were 
infected with MCMV. In a wildtype mouse, the Ly49H+ population of NK cells expands from 
~50% to ~90% of NK cells over the course of MCMV infection (Supplementary Fig. 3.1C, Fig. 
3.3A). On day 5 post-infection, Ncr1-Cox10D/D mice had significantly fewer Ly49H+ NK cells than 
control mice, both in proportion and absolute number (Fig 3.3A, B). For example, in the spleens 
of female mice, 62.4±4.7% of NK cells were Ly49H+ in Ncr1-Cox10D/D mice compared to 
81.5±3.8% in WT. Additionally, Ncr1-Cox10D/D mice had fewer overall NK cells in the spleen 
than wild type mice (Fig. 3.3C). This was primarily due to loss of Ly49H+ cells, as there was no 
significant difference in the number of Ly49H- cells (Fig. 3.3B). 
We asked if this was due to a proliferative defect, or increased death of Cox10-deficient NK cells. 
In both male and female mice, preferential Ly49H-driven proliferation measured by BrdU uptake 
during MCMV infection was lost, with Ly49H- NK cells taking up the same amount of BrdU as 
Ly49H+ NK cells in Ncr1-Cox10D/D mice (Fig 3.3D). Only in male mice, which were infected at a 
higher dosage, was BrdU uptake decreased overall in Cox10-deficient NK cells compared to 
wildtype (Fig. 3.3D). The proportion of cells staining for Annexin V (apoptotic) and/or 7AAD 
(dead) was not significantly elevated in proliferating Cox10-deficient NK cells (Fig. 3.3E) or in 
bulk splenocytes (Fig. 3.3F). Although dying and dead cells are cleared quickly in vivo, these 
preliminary results suggest that decreased expansion of Ly49H+ NK cells in the absence of Cox10 
was more likely due to a proliferative defect rather than death of the proliferating cells. 
In vitro model of Ly49H-driven proliferation also requires Cox10 
In order to model MCMV infection in vitro, we used the pro-B cell Ba/F3 line expressing 





Figure 3.3. Cox10-deficiency leads to decreased expansion of the Ly49H+ population of NK cells during MCMV 
infection. Mice were infected i.p. with MCMV and assessed at day 5 post-infection. Black circle, WT (Ncr1-YFP); 
orange square, Ncr1-Cox10D/D. A-C) Females infected at 5e4 PFU, n=8-9 individuals/group in 2 separate experiments; 
males at 7.5e4-1.25e5 PFU, n=7 in 2 exp. A) % of Ly49H+ cells amongst YFP+ (Cre-induced) NK cells was measured 
in the spleen and blood by flow cytometry. The number of B) Ly49H+ NK cells and C) NK cells per spleen. D) BrdU 
was given i.p. 3 hours before spleens were harvested for analysis at day 5 post-infection. The percentage of YFP+ NK 
cells that had incorporated BrdU was measured by intranuclear flow cytometry (females at 5e4 PFU, n=4-5 
individuals/group; males at 7.5e4 PFU, n=4/group; single experiments). Rate of apoptosis as measured in E) Ly49H+, 
YFP+ splenic NK cells or F) all splenocytes by staining with Annexin V (AnnV) and/or 7AAD. Representative flow 
plots and summary data shown (females at 5.4-7.5e4 PFU, n=7-9/group, 2 experiments; males at 7.5e4 PFU, 




with 10ng/mL IL-15 for two days to mimic inflammatory conditions early during infection, and 
then co-cultured with Ba/F3-m157 cells for three additional days to mimic viral proliferative 
stimuli. During Ba/F3-m157 co-culture, Ly49H+ NK cells that recognize the m157 ligand 
preferentially expand. As controls, cells were exposed to 10ng/mL or 100ng/mL IL-15 for five 
days for minimal and maximal proliferation. We found that Cox10-deficient Ly49H+ NK cells 
proliferated significantly less in response to Ba/F3-m157 stimulation than their wildtype 
counterparts (Fig. 3.4A). On the other hand, there was no pronounced difference in proliferation 
of cells that had been stimulated by 100ng/mL IL-15 (Fig 3.4B).  
Based on these findings, we explored possible mechanisms for the observed proliferation 
defect. Cox10-deficient T cells had increased rates of apoptosis after activation through the T cell 
receptor (17). This did not appear to be the case in NK cells, as there were no significant differences 
between Cox10-deficient and wildtype NK cells in the proportion of apoptotic and dead by 
Annexin and 7AAD staining (Fig. 3.4C). Cox10-deficient NK cells did have decreased levels of 
mitochondrial reactive oxygen species (ROS) as noted by MitoSOX staining after proliferation 
(Fig. 3.4D). However, Cox10-deficient NK cells could proliferate in response to high-dose IL-15 
despite decreased levels of ROS (Fig. 3.4D), suggesting that mitochondrial ROS may not be 
required for all NK cell proliferation. In summary, our in vitro MCMV model using two day IL-
15 priming + three day Ba/F3-m157 proliferation revealed proliferation defects in Cox10-deficient 
NK cells that were not present in NK cells activated with short-term stimulation or high-dose IL-





Figure 3.4. Cox10 deficiency also causes NK cell proliferation defects with Ly49H stimulation in vitro. 
Splenocytes from and Ncr1-Cox10D/D  and Ncr1-YFP (WT) mice were cultured in A) 10ng/mL IL-15 for 2 days, then 
BaF3-m157 cells were added at a 1:10 to 1:5 Ba/F3-m157:splenocyte ratio for the next 3 days, or B) IL-15 at 10ng/mL 
or 100ng/mL for 5 days. Proliferation after 5 days was measured by % of cells diluting CellTrace Violet. 
Representative flow cytometry and summary data shown (n=4-6 individuals/group in 3 separate experiments). C) 
Samples from B were stained for Annexin V (AnnV) or 7AAD to assess for apoptotic and dead cells, respectively; 
dead cells include cells staining with either dye. Representative data shows technical triplicates from one of two 
experiments. D) Samples from B, gated on YFP+ NK cells, were stained with MitoSOX for reactive oxygen species; 
representative data show technical triplicates from one of three experiments. ns=not significant (p≥0.05), *=p<0.05 
by matched 2-way ANOVA. 
Cox10 deficiency leads to increased susceptibility to MCMV 
 Next, we asked whether the defect in expansion of Cox10-deficient Ly49H+ NK cells was 
associated in vivo with changes in viral control and mouse survival. Previous studies have shown 
that female mice are more susceptible to MCMV than male mice (26), so we infected each gender 
with different doses. We found that, in males infected with a low dose of MCMV (7.5e4 PFU, 
~11% of male LD50)(26), Ncr1-Cox10D/D mice had significantly higher viral copy numbers in the 
spleen and liver (Fig. 3.5A). This difference was not significant in females infected with a low 
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dose of MCMV (5e4 PFU, ~19% of female LD50)(Fig. 3.5B). However, female mice infected with 
a higher dose (2e5 PFU, ~74% of LD50) did have a survival defect in a single experiment, with 
33% mortality in Ncr1-Cox10D/D (Fig. 3.5C). These data suggest that loss of Ly49H-driven 
expansion of Cox10-deficient NK cells may cause increased susceptibility to infection in a dose- 
or sex-specific manner. 
 
Figure 3.5. Increased MCMV susceptibility in Ncr1-Cox10D/D mice. (A-B) Mice were infected with i.p. with 
MCMV, and at day 5 post-infection spleen and liver were processed for DNA extraction. MCMV levels were assessed 
by qPCR for MCMV gene ie1, and normalized to b-actin levels. A) Male mice were infected with 7.5e4 PFU (n=4-
9/group, single experiment). Controls are both Ncr1-WT and littermate Cre- Cox10flox. B) Female mice infected with 
5e4 PFU MCMV (n=8-9 individuals/group, 2 separate experiments). Copy number data was analyzed by t-test on log-
transformed data, SEM shown. C) For susceptibility, female mice were infected with 2e5 PFU MCMV i.p. and 
followed for 10 days (n=6 individuals/group, single experiment).  
Formation of “memory” NK cells decreased after adoptive transfer of Cox10-deficient NK cells 
Since we found that Ncr1-Cox10D/D mice are more susceptible to infection, we wanted to 
rule out the possibility that higher viral burdens or decreased cytokine production were 
contributing to the apparent defect in Ly49H+ NK cell expansion in Ncr1-Cox10D/D mice. To do 
this, we used an adoptive transfer model used to examine formation of Ly49H+ “memory” NK 
cells during MCMV infection (22). Cox10-deficient and control NK cells were co-transferred into 
Ly49H-deficient Bxd8 mice that were then infected with MCMV. The peak of expansion of 
Ly49H+ NK cells occurs at day 7 post-infection, after which they contract to form a “memory” 
population (22). Using this system, we tracked the expansion of the Ly49H+ population during 
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MCMV, using YFP to distinguish between Cox10-deficient (YFP+) and control (YFP-) NK cells 
(Fig. 3.6A). We found that Cox10-deficient NK cells hardly proliferated in competition with 
control NK cells. Cox10-deficient and wildtype NK cells were adoptively transferred at a 1:1 ratio, 
but after 7 days of infection, Cox10-deficient NK cells comprised less than 10% of all Ly49H+ NK 
cells (Fig. 3.6B). In fact, virus-driven expansion was not detected in Cox10-deficient Ly49H+ NK 
cells (Fig. 3.6C). Thus, co-transfer shows that Cox10-deficient and WT NK cells have a cell-
intrinsic defect in proliferation that is not due to cell-extrinsic factors such as differences in viral 
titer. 
 
Figure 3.6. Lack of proliferation of Cox10-deficient NK cells leads to few MCMV-adapted “memory” NK cells. 
A)  Ncr1-Cox10D/D splenocytes (>80% NK cells were YFP+) were mixed with splenocytes from littermate Cox10D/D 
(YFP-) mice and adoptively transferred to B6.Bxd8 mice, which lack Klra8, the Ly49H receptor. The next day, 
B6.Bxd8 mice were infected i.p. with 2000 PFU MCMV. Blood was acquired by cheek bleed every 7 days after 
infection, out to day 28, and the YFP+ to YFP- ratio of Ly49H+ NK cells was assessed. Mice were sacrificed at day 
28, for which spleen and blood data were averaged. B) Competition assay showing the preferential expansion of 
wildtype (YFP-) NK cells and loss of Cox10-deficient (YFP+) NK cells. C) Overall expansion of the YFP+ and YFP- 
Ly49H+ populations compared to all NK cells in the Bxd8 mouse. N=5-8 individuals/group, 3 separate experiments, 
both sexes represented. Error bars show SEM. Statistics by 2-way ANOVA, with Ncr1-Cox10 D/D vs. Cox10 D/D shown, 
ns = not significant (p≥0.05), *** p<0.001. 
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In this model, a population of “memory” Ly49H+ NK cells is present that persists for over 
a month (27). In contrast, Cox10-deficient “memory” NK cells never expanded and were difficult 
to detect in the spleen and blood after about 21 days post-infection (Fig. 3.6C). This experiment in 
B6.Bxd8 mice shows that the production of “memory” in response to MCMV infection was 
hindered in Cox10-deficient NK cells due to their inability to expand their Ly49H+ population. 
3.4 Discussion 
We have shown that NK cells lacking Cox10, which encodes a necessary subunit for 
assembly of cytochrome c oxidase (Complex IV of the ETC), had normal development and energy 
generation at baseline. However, Cox10-deficient NK cells had a defect in expanding in response 
to Ly49H stimulation, which we found both in vivo during MCMV infection and in vitro using 
Ba/F3-m157 cells. This defect appears to be cell-intrinsic and associated with decreased 
proliferation and decreased ROS production rather than increased rates of apoptosis. On the other 
hand, proliferation of Cox10-deficient NK cells in response to high-dose IL-15 was normal. 
Defective Ly49H+ expansion led to increased susceptibility to MCMV in Ncr1-Cox10D/D mice and 
failure to generate “memory” NK cells. This is the first study to describe the role of oxidative 
metabolism in NK cell antiviral responses. 
Given that NK cells have been shown to be primarily reliant on oxidative phosphorylation 
for energy generation at baseline (8), it was interesting to note that NK cell development and 
energy production at baseline was normal. It may be possible that COX turnover is slow relative 
to the lifespan of each NK cell, so that sufficient levels of Complex IV are present to produce ATP 
in resting cells. It might not be until cells are sufficiently stimulated, or induced to have their 
existing mitochondria turned over, that the lack of Cox10 affects cellular function and remaining 




be increased during MCMV infection (28), which may trigger defects in Cox10-deficient NK cells. 
We did find defects in proliferative ability and production of mitochondrial ROS when Cox10-
deficient NK cells were activated. Another possibility is that NK cells rely on alternate pathways 
such as aerobic glycolysis to fuel their ATP production and function. This would not explain the 
fact that we did not find a consistent decrease in oxygen consumption in our Cox10-deficient NK 
cells, as COX is the major oxygen-consuming enzyme complex in the cell.  
We found that activated Cox10-deficient NK cells produce decreased levels of 
mitochondrial ROS compared to wildtype NK cells, which is a possible mechanism for how Cox10 
deficiency causes decreased NK cell proliferation. In T cells, ROS are known to assist in signal 
transduction (7, 29), so it is possible that signaling downstream of activating stimuli are affected 
by Cox10 deletion. While T cell activation leads to production of ROS from several sources, the 
major mitochondrial sources are superoxide radicals from Complexes I and III. These radicals 
form H2O2, which can sulfenylate proteins and alter their function, e.g. altering phosphorylation 
cascades (7). Although H2O2 can cross membranes, it is not entirely clear how much mitochondrial 
ROS affects signaling at the plasma membrane. In fact, there is evidence suggesting that T-cell 
proliferation does not require intracellular ROS, though proliferation can be blocked by exogenous 
ROS produced by phagocytes & neutrophils (7). Little is known about the role of ROS in NK cell 
signaling. In vitro, neither exogenous nor cell-intrinsic H2O2 affects IFN-g production during 6 
hour stimulation (8). Its role during MCMV infection is also unclear. NK cells increase their 
mitochondrial ROS production by day 7 post-infection, but mitophagy is required for contraction 
of Ly49H+ NK cells into a “memory” pool, which suggests that high ROS levels are detrimental 
for maintenance of “memory” NK cells (28). In NK cells, we have evidence that COX10 




of the activating stimulus. Further study is required to discern whether or not changes in 
mitochondrial ROS production affect signaling cascades downstream of Ly49H or other activating 
stimuli and lead to decreased proliferation. 
It appears that Cox10 deficiency has different effects in T cells and in NK cells. Both 
Cox10-deficient T cells and NK cells proliferated more slowly with receptor stimulation (CD3 + 
CD28 or Ba/F3-m157 co-culture, respectively) (17). However, Cox10-deficient T cells had higher 
rates of apoptosis after activation (17), which was not noticed in Cox10-deficient NK cells. Thus, 
the involvement of mitochondrial signaling in apoptosis after activation appears to be different in 
NK cells and T cells. In T cells, activation-induced cell death has been linked to mitochondrial 
ROS production (5); this may not be the case in NK cells. Also, cytochrome c is a key regulator 
of apoptosis. Since COX plays a role in cytochrome c control, Cox10 deficiency might alter 
cytochrome c regulation and lead to induction of apoptosis. If this is occurring in T cells but not 
NK cells, NK cells may have a way to avoid triggering this pathway. 
Multiple studies have found that IL-15 fundamentally alters NK cell metabolism; here, we 
show that IL-15-treated NK cells overcome Cox10 deficiency. Cox10-deficient NK cells 
stimulated with high-dose IL-15 do not have a defect in proliferation compared to co-culture with 
Ba/F3-m157 cells. This may be due to differences in signaling pathways downstream of cytokines 
compared to activating receptors, as we have previously shown these two activation pathways are 
differentially-regulated by OXPHOS in resting NK cells (8). However, high-dose IL-15 is also 
known to upregulate the rate of glycolysis and OXPHOS and change metabolic requirements for 
activation (8, 10, 29). The IL-15àPI3KàAKTàmTOR signaling pathway has been shown to be 
required for normal NK cell function, including proliferation during MCMV infection (29, 30). 




signals downstream of IL-15 may allow cells to use aerobic glycolysis or other non-oxidative 
pathways to compensate for decreased COX function. 
We show here that NK cell expression of Cox10 is required for optimal NK cell antiviral 
responses. MCMV infection can be controlled by cytokine production and NK cell killing before 
Ly49H+ expansion begins (18), which we have yet to examine in Ncr1-Cox10D/D mice. However, 
our data suggest that at higher doses, deficient expansion of the Ly49H+ population is associated 
with increased viral copy number and increased susceptibility to infection. Additionally, we used 
adoptive transfer into Ly49H-deficeint B6.Bxd8 mice to show that loss of Cox10 led to failure to 
expand the Ly49H+ NK cell population when competing with wildtype Ly49H+ NK cells. This 
competition assay controls for possible effects of viral titer, killing, and cytokine production, 
indicating that the defect in expansion is cell-intrinsic. This assay also showed that loss of Cox10 
led to failure to produce a MCMV-adaptive “memory” NK cell pool. While memory T cell 
generation is associated with increased mitochondrial mass and oxidative capacity (1), NK cell 
memory generation is associated with clearance of dysfunctional mitochondria (28), suggesting 
that the metabolisms underlying NK and T cell memory are very different. This model did not 
allow us to examine the role of Cox10 and oxidative metabolism in the contraction to form a 
memory pool and the maintenance of enhanced survival and function associated with memory; 
work using inducible Cre models will be necessary to ascertain whether memory NK cells are as 
highly oxidative as memory T cells are. However, our data suggest that OXPHOS is required for 
initial proliferation to generate memory in NK cells. 
In conclusion, we have found that deficiency in the mitochondrial OXPHOS-related gene 
Cox10 leads to deficient expansion of the Ly49H+ NK cell population during MCMV infection, 




Cox10-deficient NK cells appear normal, but have in deficient proliferation in vitro with Ly49H 
stimulation, though not with IL-15 stimulation. Cox10-deficient NK have decreased production of 
mitochondrial ROS, which we speculate may lead to altered signaling or mitochondrial function 
to cause decreased proliferation. These studies describe an initial foray into using genetic models 
of oxidative metabolism deficiency to investigate the metabolic regulation of NK cell functions, 
including antiviral responses, in vivo. We show that oxidative metabolism is required for normal 
NK cell responses to MCMV infection. 
 
3.5 Materials and Methods 
Mice and MCMV infection 
All mice were maintained in specific pathogen-free conditions, bred in-house, used 
between 8-12 weeks of age, and euthanized in accordance with institutional guidelines. Cox10 
floxed mice (14) and YFP reporter mice, where YFP is driven by the Rosa26 promoter (31), were 
purchased from Jackson Laboratories. They were bred to Ncr1-Cre mice (32) to produce Ncr1-
Cox10D/D mice. All mice were on the C57BL/6 background. 8-12 week old mice were injected i.p. 
with 0.5 x 104 - 2 x 105 PFU of Smith strain salivary gland MCMV (ATCC, prepared in BALB/c 
mice), or media as a control. To assess proliferation during MCMV infection, mice were injected 
with 2mg BrdU (BD Biosciences) i.p. 3 hours before harvest. For memory experiments, with 20-
30 x 106 splenocytes were adoptively transferred into Ly49H-deficient Bxd8 mice, which were 
then infected with 2 x 103 PFU MCMV 18-24 hours later. Ly49H+ expansion was tracked through 
bleeding from the cheek vein. 




 Murine NK cells were enriched from spleens using negative selection beads, using EasySep 
Mouse NK Cell Isolation Kits (StemCell Technologies) according to manufacturer’s directions. 
Sorting was accomplished on a FACSAria Fusion sorter (BD) using FACSDiva software (BD). 
In vitro cell assays 
Primary splenocytes from mice were cultured in RPMI 1640 (Mediatech) supplemented 
with 10% FBS (Sigma-Aldrich), L-glutamine to a final concentration of 4mM (Sigma), 50µM 2-
ME (Sigma), and antibiotics (penicillin/streptomycin). Ba/F3-m157 (from W. Yokoyama) were 
cultured in R10 supplemented with puromycin for selection of m157 expression and 5% IL-3- 
containing supernatant from X63 cells. NK cells were enriched from spleens using negative-
selection magnetic bead kits (StemCell Technologies).  
For short-term stimulation assays, NK cells were stimulated with 10 ng/ml murine IL-12 
(PeproTech) and 50ng/mL murine IL-15 (MBL), or 10ng/mL IL-15 and 100 ng/ml IL-15. Ab 
stimulation was performed by culturing splenocytes or enriched NK cells in plates coated with 20 
μg/ml purified anti-NK1.1 (PK136; BioXcell), 40ug/mL purified anti-Ly49H (3D10, BioXcell), 
or 40ug/mL IgG2A control (BioXcell). Brefeldin A was added to cells after 1 h of culture to inhibit 
secretion of IFN-γ. Intracellular IFN-γ production was assayed using BD Cytofix/Cytoperm (BD 
Biosciences), as recommended by the manufacturer. 
For proliferation assays, cells were stained with 2.5-5µM CellTrace Violet before culture. 
Splenocytes were cultured in 10ng/mL murine IL-15 (PeproTech) for two days, and then Ba/F3-
m157 cells were added at a 5:1 to 10:1 splenocyte:Ba/F3-m157 ratio for three additional days.  For 
purified NK cells, cells were cultured in 20ng/mL IL-15 for two days, then Ba/F3-m157 cells were 
added at approximately a 1:1 ratio for three additional days. As controls, cells were cultured in 10-





Cell viability was measured by cell counts on a hemacytometer with trypan blue staining, 
live/dead stain (Zombie Yellow, BioLegend), or incubation with 7-aminoactinomycin D (7AAD, 
Calbiochem) for 15-60 minutes. Cells were blocked with anti-FcγRIII (2.4G2) prior to surface 
staining. Cells were fixed with 1% paraformaldehyde for surface analysis, or fixed with 
Cytofix/Cytoperm (BD Bioscience) for intracellular staining. For intranuclear staining, cells were 
fixed in Cytofix/Cytoperm and Cytoperm Plus buffer (BD) and DNAse treated. Data was acquired 
on a Cytek-modified FACScan (BD and Cytek) or LSRFortessa (BD); data was analyzed using 
FlowJo 7.6.5. Geometric mean fluorescence intensity and % proliferated were calculated by 
FlowJo. The following fluorochrome-conjugated antibodies were used: Annexin V (Apoptosis 
Detection Kit I, BD), BrdU (BrdU kit, BD), CD3ε (145-2C11, BD/BioLegend), CD11b (M1/70, 
BD), CD19 (eBio1D3, eBiosciences), CD49b (DX5, BioLegend), CD122 (TM-Beta1, BD), 
DNAM-1 (10E5, BioLegend), anti-human Gzmb (GB12, Invitrogen/Life Technologies), IFN-γ 
(XMG1.2, BioLegend), KLRG1 (2F1, Sirigen/BioLegend), Ly49C/I (BD), Ly49D (4E5, 
BioLegend), Ly49H (3D10, BD/BioLegend), NK1.1 (PK136, BD), NKG2A/C/E (20d5, BD), 
NKG2D (CX5, Biolegend) and NKp46 (29A1.4, BD).  
Transmission Electron Microscopy 
For ultrastructural analyasis, sorted NK cell pellets were fixed in fresh 2% 
paraformaldehyde/2.5% glutaraldehyde fixative (Polysciences) in 100mM sodium cacodylate 
buffer, pH 7.2 for 1 hour at room temperature. Samples were washed in sodium cacodylate buffer 
and postfixed in 1% osmium tetroxide (Polysciences) for 1 hour. Samples were then rinsed 
extensively in dH2O prior to en bloc staining with 1% aqueous uranyl acetate (Ted Pella) for 1 




embedded in Eponate 12 resin (Ted Pella). Sections of 95 nm were cut with a Ultracut UCT 
ultramicrotome (Leica Microsystems), stained with uranyl acetate and lead citrate, and viewed on 
a JEOL 1200 EX transmission electron microscope (JEOL USA) equipped with an AMT 8 
megapixel digital camera and AMT Image Capture Engine V602 software (Advanced Microscopy 
Techniques). 
ATP assay 
Purified NK cells were plated at 5 x 104 to 1 x 105 cells/well in a 96-well Optilux plate and 
ATP production was assessed using the ATPLite Luminescence Assay Sytem (Perkin Elmer) 
according to the manufacturer’s protocol. Briefly, cells were lysed and exposed to luciferin, then 
dark-adapted. Luminescence was read on a Synergy 2 Multi-Dection Microplate Reader (BioTek). 
Values were obtained by comparison to a standard curve and normalized to pMol ATP per million 
cells. 
Extracellular flux 
 Extracellular flux assays were performed using a XF96 Analyzer (Seahorse Bioscience). 
Cell were washed and plated on poly-L-lysine-coated plates in at least duplicate for extracellular 
flux analysis of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) as 
previously described (10, 76). Mitochondrial stress tests were performed in Seahorse XF media 
with glucose, L-glutamine, sodium pyruvate, and 1% FBS (pH 7.4). Drug concentrations during 
the assay were: 10µM oligomycin, 10µM FCCP, 10µM rotenone, and 10µM antimycin A. 
Cox10 quantitative PCR 
 Enriched NK cells were sorted on YFP expression and lysed in TRIzol (Thermo Fischer), 
for serial extraction of RNA, DNA, and protein according to the manufacturer’s directions. cDNA 




was from IDT, and b-actin primer/probe set was from Applied Biosystems. Fold change was 
calculated using the DDCt method. 
MCMV quantitative PCR 
 5mm3 tissue pieces were minced and placed in Gentra Puregene Cell Lysis Buffer 
(Qiagen), and DNA extracted following the manufacturer’s recommended protocol and diluted to 
20-50ng/ml. MCMV immediate-early gene 1 (ie1)-specific primers and probe were used to 
determine viral copy number as described (47), and normalized to b-actin (Actb). Reactions were 
run in duplicate in on a 7500 Fast Real-Time PCR instrument (Applied Biosystems) with an 
absolute standard curve. The limit of reliable detection using the standard was 100 copies of 
MCMV, and all values below 100 were rounded up. Graphs represent [(copies MCMV ie1)/(copies 
Actb)] x 1000. Statistics were performed on log-transformed data. 
Statistics 
Statistics calculated in Prism 7 include mean, standard deviation, standard error of 
measurement (SEM), student’s t-test, Log-rank Mantel-Cox test, ordinary one-way or two-way 
ANOVA. All treatment groups used in an experiment were included in the ANOVA analysis, 
including controls; in non-survival experiments, mice that appeared uninfected were excluded 
from analysis. Tukey’s test and Sidak’s test were used to correct for multiple comparisons, and 
adjusted p values are shown. P values represent 2-tailed probability, a=0.05. Data are presented 
with data averaged from each mouse or experiment as a separate point, or as mean±SEM.  
Animal study approval 
All animal studies were performed at Washington University using an Animal Studies 




3.6 Supplementary Figures 
 
Supplementary Figure 3.1. Normal development of Cox10-deficient NK cells. Organs were collected from 8-12 
week old mice of both sexes. Bone marrow (2 femur, 2 tibia) n=7 individuals/group, 3 separate experiments. Liver 
n=7, 3 exp. Lung n=8-9, 3 exp. Lymph node (average of axillary & inguinal) n=8-9, 3 exp. Spleen, n=10-11, 3 exp. 
Blood n=10, 4 exp. Black circles = WT, orange squares = Cox10D/D. Statistics by unpaired t-test, error bars show SEM. 
ns=not significant (p≥0.05). A) % NK cells and % YFP+ of all NK cells were assessed by flow cytometry. # of YFP+ 
NK cells was calculated based on cell counts. B) Representative flow showing maturity by CD11b x CD27 staining 
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Chapter 4  






In this dissertation, we examined the role that metabolic pathways—specifically glycolysis 
and oxidative phosphorylation—play in regulating NK cell function during viral infection. In the 
following section, we review data from the two models we used to manipulate metabolism during 
infection with murine cytomegalovirus (MCMV): injection of a glycolytic inhibitor drug, and NK 
cell-specific genetic deletion of Cox10, a subunit of mitochondrial electron transport chain 
Complex IV. Then, we discuss how these findings relate to the greater body of work in the field 
of immunometabolism and NK cell regulation. Finally, we suggest new areas of study based on 
our findings. 
4.1 Glycolytic Metabolism in NK Cell Antiviral Function 
 Previous work examining the role of glycolysis in NK cell function shows that while naïve 
murine NK cells are dependent on glucose for survival, glycolysis is required for short-term IFN-
g production downstream of NK activating receptor (NKR) activation, but not cytokine activation 
(1). Human NK cells also depend on glycolysis for IFN-g production in response to certain stimuli 
(2). Most of this work has been done in vitro, so studies in vivo are necessary to understand how 
glycolysis regulates other NK cell functions in physiological contexts such as during viral 
infection. While mTOR has been shown to be required for NK cell function in response to MCMV 
infection (3, 4), it is not known whether mTOR is required because of its upregulation of 
glycolysis, or because of its other functions. We hypothesized that NK cells require upregulation 
of glycolysis in order to fuel their antiviral function during MCMV. 
In order to examine the role of glycolysis in NK cell antiviral function, we used injection 
of the glucose metabolism inhibitor 2-deoxy-ᴅ-glucose (2DG) to non-specifically inhibit glucose 




mouse, we found that NK cell production of IFN-g at 36 hours post-infection and proliferation of 
Ly49H+ NK cells at 4 days post-infection was normal, indicating 2DG-treated NK cells were 
responsive to inflammatory cytokines and proliferated normally. However, we found that 
clearance of m157-expressing targets in vivo was inhibited by 2DG treatment. Decreased NK cell 
killing in 2DG-treated mice was associated with poor control of viral infection and led to death in 
the majority of mice around day 6 of infection. Using in vitro assays to explore potential 
mechanisms, we found that killing defects were present when murine and human NK cells were 
treated with 2DG during priming with IL-15. This was associated in vitro with altered actin 
accumulation at the immunological synapse and decreased Gzmb production in murine 2DG-
treated NK cells, providing two potential mechanisms for deficient killing.  
Treatment with IL-15 has been shown to alter NK cell function, including their metabolic 
requirements for function (1). We found that pre-treatment of mice with the recombinant IL-15 
superagonist ALT-803 was able to maintain high levels of NK cell killing and protect mice from 
2DG-induced susceptibility to MCMV in an NK-dependent manner. Additionally, ALT-803-
treated mice were also resistant to the effects of mTOR inhibitor rapamycin, which lies 
downstream of IL-15 and upregulates glycolytic metabolism. Combining this data with work by 
others examining the role of mTOR in IL-15 signaling (4, 5), we speculate that mTOR signaling 
and upregulation of glycolysis are required for IL-15 priming, but after priming has occurred, NK 
cell function is independent of both mTOR and glycolysis. 
In conclusion, 2DG treatment in vitro inhibited IL-15 priming of multiple NK cell 
functions, while 2DG treatment in vivo led to selective loss of NK cell cytotoxicity. Decreased 
killing was associated with altered actin dynamics at the immunological synapse, and was 




2DG treatment restored normal cytotoxicity and resistance to infection. These findings indicate a 
key role for glycolysis in NK cell antiviral functions, with NK cell killing especially dependent on 
glucose metabolism. Interestingly, NK cell proliferation in vivo did not appear to require a 
transition to aerobic glycolysis as has been described in other immune cell types. This may indicate 
that NK cell proliferation is regulated much differently than in other immune cells, or that 
additional signals in vivo compensate for glycolytic inhibition. Finally, our results showing ALT-
803 enhances NK cell function and aids in clearance of CMV viremia suggests that treatment with 
ALT-803 may help NK cells clear other refractory viral infections in patients. 
 
4.2 Oxidative Metabolism in NK Cell Antiviral Function 
 Previous work examining the role of oxidative and mitochondrial metabolism in NK cells 
has been more limited than for glycolysis. Blockade of ATP synthesis using oligomycin was shown 
to inhibit IFN-g production in murine NK cells activated through NKRs but not cytokine receptors 
(1), as well as in human NK cells activated by IL-12 + IL-15 (2). Also, activation of NK cells 
during MCMV was associated with increased mitochondrial reactive oxygen species (ROS) 
production, while successful formation of the Ly49H+ memory population required mitophagy (6). 
As discussed above, we found that glycolysis was required for NK cell killing, but not cytokine 
production or proliferation, during MCMV infection. Based on these findings, we hypothesized 
that oxidative metabolism is required for NK cell antiviral functions that were not dependent on 
glycolysis, such as proliferation, as well as formation of “memory” NK cells. 
To investigate the role of oxidative metabolism during MCMV infection, we used genetic 
deletion of the Complex IV assembly factor COX10 to inhibit oxidative metabolism in an NK-




production, and IFN-g production in response to short-term stimulation. However, we found that 
Cox10-deficient NK cells had poor expansion of Ly49H+ cells that respond specifically to the 
m157 ligand during MCMV infection. An in vitro model showed Cox10-deficient NK cells had 
poor Ly49H-driven proliferation but normal IL-15-driven proliferation. The role of Cox10 in NK 
cell IFN-g production and killing during MCMV infection remains to be examined. However, a 
co-transfer experiment showed that the expansion defect in Cox10-deficient NK cells was cell-
intrinsic. Ncr1-Cox10D/D mice appear to be more susceptible to infection than wildtype, although 
these effects may be dependent on the dose of virus and/or the sex of the mouse. Additionally, 
production the Ly49H+ “memory” NK cell pool, which persists with higher function for weeks to 
months after infection, was severely inhibited in Cox10-deficient NK cells.  
How Cox10 deficiency leads to decreased Ly49H+ expansion is not yet clear. Preliminary 
data from both in vitro and in vivo experiments suggest that the expansion defect in Ly49H+ 
Cox10-deficient NK cells as not associated with increased rates of apoptosis after activation, which 
occurs in Cox10-deficient T cells. One possible mechanism is that decreased NK cell proliferation 
in Cox10-deficient NK cells is due to decreased production of ROS, which are known to contribute 
to signaling in T cells.  
In conclusion, NK cell-specific deletion of Cox10 did not affect NK cell development, but 
did impair the ability of the cells to expand the Ly49H+ pool in response to both MCMV infection 
and in vitro co-culture with Ly49H-stimulating target cells. This expansion defect in Cox10-
deficient NK cells was cell-intrinsic and not due to increased apoptosis of activated cells, but may 
be related to their decreased production of ROS. Finally, Cox10 deficiency in NK cells led to 
increased susceptibility to infection and poor formation of “memory” NK cells. These findings 




They also imply that NK cells may have flexible fuel requirements for development and short-
term function, and suggest that ROS may play a role in regulating NK cell function, which has not 
been shown before. 
 
4.3 NK Cells in the Immunometabolism Paradigm 
NK cells are the closest, developmentally and functionally, to CD8+ T cells. My original 
hypothesis was that NK cells would be similar to CD8+ T cells in their metabolic regulation, 
especially for the periods of extended activity required for antiviral responses. CD8+ T cells have 
been well-described to require aerobic glycolysis (but not oxidative phosphorylation) for their 
activation and proliferation through their T cell receptor, and to require decreased glycolysis and 
increased oxidative metabolism during their transition to memory (7-10). To my surprise, we were 
able to inhibit NK cell proliferation in vivo by impeding oxidative metabolism but not glucose 
metabolism. In fact, it was NK cell cytotoxicity that was especially sensitive to glycolytic 
regulation, which was not expected as NK cell killing can occur without the extended activation 
(≥18h) required for upregulating glycolysis in murine NK cells. While the discrepancy between 
results in T cells and NK cells as differences may reflect the differences in in vitro and in vivo 
inhibition (as we were able to block NK cell proliferation using 2DG in vitro), our findings 
nevertheless suggest that NK cells are regulated significantly differently at a metabolic level 
compared to CD8+ T cells. Our work examining the role of metabolic regulation of cytotoxicity in 
NK cells also provides a basis for much-needed work examining metabolic regulation of CD8+ T 
cell cytotoxicity. 
Another of my initial hypotheses was that both T and NK cell memory would be associated 




enhanced longevity and increased functional capacity upon reactivation has been associated with 
increased mitochondrial mass and spare respiratory capacity. We found that Cox10-deficient NK 
cells form almost no memory population in a co-transfer model, although this is likely due to their 
inability to proliferate and may not reflect the changes undergone by wildtype NK cells to form 
memory. However, another group has shown that production of “memory” NK cells requires 
mitophagy, or the recycling of mitochondria that are over-activated and producing too many ROS 
(6). They show that “memory” NK cells have less mitochondrial mass than naïve or MCMV-
activated NK cells. If this is true—that NK cells require high oxidative metabolism to proliferate 
and decreased mitochondrial activity to form memory—then memory is fundamentally different 
in NK and T cells at a metabolic level. These differences could be explained by the differences in 
functional capacity of memory T cells and NK cells. While memory T cells last years, we are not 
sure that NK cell “memory” lasts beyond months (11). If this is the case, then memory T cells may 
rely more heavily on mitochondria for their longevity while the shorter-lived “memory” NK cells 
do not prioritize long-term survival.   
It is also interesting to note that Cox10 deficiencies defects cause apoptosis in T cells but 
not NK cells (12). In Cox10-deficient T cells, increased apoptosis may be associated with 
decreased energy availability and/or destabilization of COX leading to cytochrome c-driven 
activation-induced cell death (13). It appears that NK cells may be avoiding these apoptotic signals 
through an unknown mechanism. 
Altogether, we have found multiple ways in which NK cells seem to violate the typical 
immunometabolism paradigm, of which T cells are the prototype; that aerobic glycolysis is 





4.4 Future Directions 
Novel mechanisms for metabolic regulation 
Our data suggest two potential mechanisms by which metabolism regulates NK cell 
function that may be novel to the field of immunometabolism. First, I hypothesize that glucose 
blockade inhibits NK cell killing by altering the stability of the immune synapse. Based on our 
findings that actin accumulation at the synapse between an NK cell and its target is more variable 
in 2DG-treated NK cells compared to untreated NK cells, I think that it is likely that some element 
of glucose metabolism is required for normal actin accumulation. For example, a specific 
metabolite may play a role in signaling at the immune synapse, or sufficient ATP must be 
generated to provide fuel and substrate for actin polymerization. Loss of actin motility can lead to 
failure to kill target cells, as granules may be unable traverse the network to the surface for 
degranulation. Another possibility is that changes in actin dynamics interfere with release of dying 
target cells by the NK cell, limiting serial killing behavior, as degranulation was normal but overall 
killing was not. 
Second, I hypothesize that a mitochondrial signal is required for signaling through NKRs, 
but that this mechanism is redundant in cells that have been primed by IL-15. In vitro, we have 
previously shown that blockade of ATP production by oligomycin inhibits NK cell activation 
through NKRs (1), and here we show that COX10 deficiency affects proliferation in response to 
Ly49H, but not IL-15. NKRs have different signaling pathways downstream than cytokine 
receptors, one of which may be metabolically regulated. Our current best guess for metabolites 
that may be involved in this signaling are ROS, which are required for signaling in T cells. Cox10-
deficient NK cells have decreased production of mitochondrial ROS, but whether this observation 




signaling, leading to slower proliferation. This would possibly be the first example of ROS 
affecting signaling in NK cells. Alternately, decreased ROS might be a byproduct of decreased 
activity of the ETC, associated with but not causing decreased ATP production or interference 
with other pathways that are the true cause of the proliferation defect. Our work shows that 
proliferation is deficient in Cox10-deficient NK cells downstream of Ly49H, but I hypothesize that 
NKRs signaling through the same signaling chains as Ly49H will also be affected.  
Additionally, I support a previously stated hypothesis on how NK cell “memory” is 
regulated by metabolism. O’Sullivan et al. hypothesize that while mitochondrial function is 
upregulated during MCMV infection, increased production of ROS and high mitochondrial 
function is dangerous to NK cells, and mitophagy of these activated mitochondria is required for 
longevity of the “memory” NK cell population (6). As discussed before, this may define some of 
the functional differences between memory T cells and memory NK cells. An inducible Cre model 
is needed to test the hypothesis that NK cells will form a more stable pool of “memory” cells if 
they are induced to lose Cox10 function after Ly49H+ expansion has already occurred.   
In conclusion, investigating the mechanisms of how inhibiting metabolic pathways cause 
defects in NK cell cytotoxicity and proliferation will be the next step toward understanding the 
complex interplay between metabolism and canonical immune activation pathways in NK cells, 
as well as unearth novel forms of metabolic regulation that might be relevant in other cell types. 
The role of IL-15 in altering metabolism 
I am very interested in how IL-15 is able to so comprehensively change the metabolism 
and metabolic requirements of NK cells. We found that IL-15 priming of cytotoxicity and IL-15-
driven proliferation in vitro can be blocked by 2DG, indicating that glycolysis plays a crucial but 




occurred, NK cells are much more resilient to metabolic inhibition. We previously observed in 
vitro that IL-15 treatment for three days allowed NK cells to produce IFN-g in culture in glucose-
free media or the ATP synthetase inhibitor oligomycin (1). In this dissertation, we find that ALT-
803 pretreatment in vivo maintained high levels of NK cell cytotoxicity despite treatment with 
2DG. I hypothesize that IL-15 priming alters the epigenetic availability of metabolic regulators 
and metabolic enzymes to allow for greater metabolic flexibility. I also suspect that in order for 
IL-15 signaling to alter metabolism, glucose metabolism is required, possibly for histone 
acetylation. Epigenetic changes downstream of IL-15 might allow multiple competing metabolic 
pathways to function at once, as well as upregulate nutrient uptake, allowing for metabolic 
flexibility. This would explain the observed increase of both aerobic glycolysis and OXPHOS in 
vitro and in vivo, as well as provide the resistance to single inhibitors that we see in IL-15-primed 
NK cells.  
Therapeutic applications 
Two models that we use, MCMV and Cox10 deficiency, are especially relevant to human 
disease. MCMV and human CMV (HCMV) share many features, including production of a 
“memory” subset with increased number and enhanced function. HCMV is a major problem in 
utero and in immunocompromised individuals, and a better understanding of MCMV antiviral 
responses may help us combat persistent HCMV infection. Cox10 deficiency is known to cause 
mitochondrial disease in humans. Although immunodeficiency is not a defining feature of 
mitochondrial disease, it has been noted that such patients do have compromised immune 
responses (12). The potential role of NK cell deficiency in patients with mitochondrial disease has 




Several of our findings have the potential for therapeutic application in humans. First and 
foremost, the IL-15 superagonist ALT-803 has already been shown to help a CMV reactivation 
patient clear their viremia, and other groups are investigating its role in boosting NK cell antitumor 
immunity. Understanding how IL-15 and ALT-803 function to make NK cells more metabolically 
flexible and resistant to inhibition may also be useful for immunotherapy, as cancerous and 
infectious microenvironments are often nutrient-poor compared to conditions in circulation. 
Especially in tumors, which compete with infiltrating lymphocytes for glucose, allowing NK cells 
to be more flexible with their fuel usage might lead to enhanced NK antitumor function. ALT-803 
could be given in concert with drugs that affect metabolism in order to boost its function, ensuring 
NK cells have the fuel necessary for IL-15 priming to occur. Second, understanding how Cox10-
deficient NK cells are metabolically flexible to allow short-term function, and how their other 
functions are limited, might also help us understand and boost NK cell function in oxygen-limited 
environments such as within tumors.  
 
 We hope that by understanding the basic regulation of NK cell function by glycolysis and 
oxidative metabolism, we can contribute to both a better understanding of how diverse immune 
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